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ABSTRACT 
 
Approximately 240 million people are estimated to be chronic carriers of hepatitis B virus (HBV), 
placing them at high risk for complications like hepatocellular carcinoma (HCC) and cirrhosis. 
Infection with the virus is predominantly high in sub Saharan Africa, East and Southeast Asia. 
Current treatments are limited by the emergence of viral resistance and adverse side effects. These 
challenges prompted development of new therapy for HBV. The application of RNA interference 
(RNAi) as a form of treatment has shown successful HBV silencing. However, safe and efficient 
delivery of anti-HBV sequences remains a challenge. Recombinant adenoviruses (Ads) have a 
natural tropism for the liver, making them suitable for anti-HBV sequence delivery. Their use in 
gene therapy is limited by their ability to induce the innate and adaptive immune response, thus 
leading to diminished transgene expression. To overcome immune stimulation, third generation 
helper-dependent adenoviral vectors (HDAds), which are devoid of all their viral coding 
sequences, were developed. This study investigated the use of HDAds expressing primary micro 
RNA (pri-miRNA) sequences from the liver-specific MTTR promoter with the aim of inhibiting 
HBV replication. The anti-HBV pri-miRNA expression cassettes were successfully cloned into 
the adenoviral bearing genome and used for HDAd production. Infection of liver derived cell line 
with these HDAds resulted in efficient pri-miRNA expression and processing into expected guide 
sequences. This was accompanied by a significant inhibition of HBV replication.  Injection of the 
HDAds into mice resulted in efficient liver transduction and no significant induction of the 
inflammatory response or liver toxicity. However, as a result of high levels of HBV replication 
markers produced in the transgenic mice used, this did not translate into significant HBV 
replication inhibition.  This study therefore highlights the safety and therapeutic potential of 
HDAds against HBV infection. To demonstrate HBV gene silencing in vivo, transgenic mice 
expressing HBV replication markers will be used. 
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CHAPTER 1 
1. INTRODUCTION 
1.1 Hepatitis B Virus (HBV) 
1.1.1 Hepatitis B Virus infection  
Hepatitis B virus (HBV) mainly infects the liver to cause Hepatitis B disease. Approximately 240 
million people are chronically infected with HBV and about 686 000 people die every year from 
the infection globally (http://www.who.int/mediacentre/factsheets/fs204/en/). Infection with HBV 
can cause a variety of liver diseases, ranging from acute to chronic hepatitis, hepatocellular 
carcinoma (HCC) and cirrhosis. HBV infection is transmitted either perinatally from infected 
mother to child at birth, parenterally through sexual contact or through contact of infected blood 
and bodily fluids [Reviewed in (MacLachlan and Cowie, 2015, Arbuthnot et al., 2007)]. 
Areas with high incidences of HBV infection are sub-Saharan Africa and Asia [Reviewed in 
(MacLachlan and Cowie, 2015)].  HBV has ten genotypes (A-J) that have been described; with 
some of these genotypes further divided into sub-genotypes. These genotypes vary in their 
geographical distribution. Genotype A is commonly found in sub-Saharan Africa, India, Europe 
and North America; genotypes B and C are endemic in East and Southern Asia; genotype D is 
endemic in the middle East, India and Mediterranean regions; genotype E is endemic in sub-
Saharan Africa; genotype F is rarely found; genotype G is endemic in USA, Germany and Mexico; 
genotype H is endemic in Mexico; genotype I has been recently found in Vietnam and Laos, 
whereas genotype J has been reported in Ryukyu Islands in Japan [Reviewed in(Sunbul, 2014)]. 
 
1.1.2 HBV genome structure  
HBV is a member of a family of small, DNA containing viruses known as Hapadnaviridae. It has 
an enveloped, partly double stranded, circular DNA genome also known as relaxed-circular DNA 
(rc-DNA) that is 3.2 kb in length. The viral genome is made up of four open reading frames 
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(ORFs): the nucleocapsid (core), virus replicase (polymerase), envelope (surface) and the X ORF. 
The core ORF encodes the structural protein [the hepatitis B core antigen, (HBcAg)] as well as the 
secreted non-structural hepatitis B e antigen (HBeAg) [Reviewed in (Pollicino et al., 2014, 
Arbuthnot et al., 2007)]. The polymerase ORF encodes the viral polymerase enzyme which has a 
reverse transcriptase (RT) and ribonuclease activities.  The surface ORF encodes viral surface 
envelope protein (HBsAg), which is divided in to pre-S1, pre-S2 and the S proteins. The X ORF 
encodes the regulatory X (HBx) protein, which is highly conserved and expressed during infection 
in humans and in wood chucks (Leupin et al., 2005, Liang, 2009, Nordin et al., 2014). The viral 
genome also contains promoters, enhancers, negative regulatory elements and a single 
polyadenylation signal at which transcription of all four major mRNAs is terminated. [Figure 1.1, 
(Decorsiere et al., 2016, Moolla et al., 2002)].  
 
3 
 
 
Figure 1.1: Genome organization of the hepatitis B virus (HBV).  The HBV genome is made 
up of a circular, partly double stranded DNA. The circular and rectangular symbols show the 
elements that regulate HBV transcription. The arrows show the overlapping open reading frames 
(ORFs). Diagram adapted from (Arbuthnot et al., 2007). 
 
1.1.3 HBV replication 
Since HBV has a natural tropism for the liver, viral DNA replication occurs in the hepatocytes. 
The partially double stranded DNA (dsDNA) genome of HBV is enveloped into the nucleocapsid 
which is surrounded by the surface glycoproteins L (large), M (medium) and S (small). The 
binding and receptor recognition of the nucleocapsid is initiated by the L and M proteins. Sodium 
Taurocholate Co-Transporting Polypeptide (NTCP) was discovered to be the host entry receptor 
that interacts with HBV membrane proteins initiating entry into the host hepatocytes. During 
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infection, hepatitis virions bind to the NTCP receptor on the hepatocytes and viral entry occurs 
through endocytosis. Following entry, the viral capsid is transported to the nucleus. The relaxed-
circular DNA (rcDNA) is released and converted to covalently closed circular DNA (cccDNA). 
RNA polymerase II transcribes the cccDNA into four subgenomic messenger RNAs (mRNAs) 
and pregenomic RNA (pgRNA). The mRNAs are transported from the nucleus to the cytoplasm 
where they are translated into viral proteins. Proximal to the 5’-end, pgRNA has a ε-stem loop, 
which when bound to polymerase triggers its encapsidation. The encapsidated pgRNA is then 
reverse transcribed in to rcDNA. The rcDNA containing nucleocapsid is either enveloped and 
secreted or transported back to the nucleus to produce more cccDNA [Reviewed in (Seeger and 
Mason, 2000, Lempp and Urban, 2014, Yan et al., 2012, Morikawa et al., 2016)].  
 
 
Figure 1.2: Hepatitis B virus (HBV) replication cycle. The hepatocytes are infected by the 
virus; the virions bind to the receptor on the hepatocytes and enter through endocytosis. The 
nucleocapsid is transported to the nucleaus where the rcDNA is converted to cccDNA. RNA Pol 
II transcribes cccDNA into pgRNA and four mRNAs which are translated into viral proteins in 
the cytoplasm. The pgRNA interacts with polymerase and it is packaged and reverse transcribed 
into rcDNA. This capsid may either be recycled back into the nucleus and converted into 
cccDNA or it gets secreted out of the cell. The figure was adapted from (Morikawa et al., 2016). 
 
5 
 
 
1.1.4 Current treatment and vaccination against Hepatitis B  
The first HBV vaccine was approved in 1980 by the US Food and Drug Administration (FDA) 
and made available for use by 1982. Thus far there are three generations of HBV vaccine. First-
generation vaccines also known as plasma-derived vaccines were made from HBsAg. HBsAg was 
extracted from the blood of people who were chronically infected with HBV through a process 
known as plasmapheresis and then it was inactivated before use. Second-generation vaccines also 
known as yeast-derived vaccines were developed in the mid-1980s. These vaccines were created 
in yeast (Saccharomyces cerevisiae) transfected with HBV-DNA sequences coding for small HBV 
surface protein. Third-generation vaccines were produced in mammalian cells, these vaccines 
induce immunity against HBV and either contain a single Pre-S2 envelope protein or a 
combination of Pre-S1 and Pre-S2 envelope proteins [Reviewed in (Edey et al., 2010, Shouval et 
al., 2015)]. 
Even though these vaccines are effective against HBV, they are unable to eradicate existing HBV 
infections. Hence, HBV therapeutics are needed to manage hepatitis B. Thus far there are seven 
drugs that have been approved by FDA for the treatment of chronic hepatitis B. These are: 
nucleoside analogues (lamivudine, telbivudine and entecavir), nucleoside analogues (adefovir and 
tenofovir) and immune modulators [interferon alfa (IFN-α) and PEGylated version (PEG IFN-α)].  
Nucleoside and nucleotide analogues are phosphorylated, hence mimics naturally occurring 
nucleosides/nucleotides. However, once incorporated in to the growing DNA strands they act as 
chain terminators by inhibiting DNA polymerase [Reviewed in (Arbuthnot et al., 2007)]. 
Lamivudine was the first oral nucleoside analogue to be approved for treating chronic HBV 
infection and it has been shown to normalize alanine aminotransferase (ALT) levels (a marker of 
liver damage), induce seroconversion of HBeAg and reverses necroinflammatory activity(Lok, 
2003, Xu et al., 2015). Adefovir was approved in 2002 for treating chronic hepatitis B after it 
showed great efficacy against lamivudine-resistant mutant, whereas entecavir was approved in 
2005. Telbivudine was approved in 2006 and has been shown to be more effective in treating 
chronic hepatitis B as compared to lamivudine. Immune modulatory agents IFN- α and PEG IFN- 
α are antiviral cytokines which are secreted by the host during viral infections. Interferons function 
by augmenting the natural human immune system to fight infection caused by HBV [Reviewed in 
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(Pham et al., 2016, Piratvisuth, 2008, Karayiannis, 2003, Fung et al., 2011)]. PEGylated IFN- α 
replaced IFN- α as it had improved efficacy and pharmacokinetic properties [Reviewed in 
(Manzoor et al., 2015)]. 
The above mentioned therapeutics have several limitations e.g. poor tolerability, limited efficacy 
and higher rates of drug resistance is usually observed. Therefore, this calls for a need for novel 
therapeutics that will result in long term HBV replication inhibition with little or no resistance and 
toxicity. Several studies have explored and showed promising outcomes with RNA interference 
(RNAi-) based gene therapy approach to combat HBV infection. RNAi-based therapeutics have 
been developed in the past years as potential novel alternatives to current anti-HBV drugs and have 
shown great success (Ely et al., 2008, Grimm et al., 2006, Crowther et al., 2014). 
1.2 RNA interference  
RNAi is a nucleic acid-based mechanism used in eukaryotic systems to regulate gene expression. 
A well-studied RNAi pathway in multicellular organisms such as plants, humans, and yeast is a 
naturally occurring pathway in which small RNA molecules called microRNAs (miRNAs) serve 
as mediators of gene silencing (Uprichard, 2005, Aagaard and Rossi, 2007). These miRNAs are 
small (19-24 nucleotides), endogenous, single-stranded, non-coding RNA molecules that regulate 
gene expression transcriptionally through complementary base pairing with messenger RNA 
(mRNA) to direct site-specific cleavage of the target or repress translation (Gentile et al., 2013). 
 
1.2.1 Micro RNA biogenesis 
The biogenesis of miRNAs begins in the nucleus where genes encoding miRNAs are transcribed 
by RNA polymerase II to form capped and polyadenylated primary miRNA (pri-miRNA). An 
RNAse III enzyme called Drosha together with DiGeorge critical region 8 (DGCR8) 
(microprocessor complex) which is a double-stranded RNA-binding partner, catalyses the 
processing of the pri-miRNA to form stem-loop hairpin structures known as precursor miRNAs 
(pre-miRNAs). These are transported by exportin-5 from the nucleus into the cytoplasm through 
a nuclear pore in an ATP dependent manner where they are further processed by Dicer to produce 
mature miRNA duplexes of 21-23 nt long. One miRNA strand (guide strand) of the miRNA duplex 
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is incorporated into the RNA induced silencing complex (RISC), whereas the other miRNA strand 
(passenger strand) is degraded by unknown mechanism. This RISC complex directs the bound 
guide miRNA strand to the target messenger RNA (mRNA) where it either directs site specific 
cleavage or represses translation [Figure 1.3, (Gonzalez-Alegre and Paulson, 2007, Khraiwesh et 
al., 2012, Sun et al., 2013)]. 
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Figure 1.3: The microRNA RNA interference pathway. The biogenesis of miRNA begins in 
the nucleus where RNA Pol II transcribes miRNA genes into pri-miRNAs. Drosha and DGCR8 
catalyse pri-miRNAs into pre-miRNAs which are transported to the cytoplasm by exportin 5. 
Dicer processes pre-miRNAs into mature miRNA duplexes, the guide strand is incorporated into 
the RISC complex which directs the guide miRNA sequence to the target messenger RNA 
(mRNA) where it either directs site specific cleavage or represses translation. Figure adapted 
from (Macfarlane and Murphy, 2010). 
 
1.2.2 Manipulation of RNAi for Hepatitis B treatment 
The ability to tap into RNAi pathway has led to the development of RNAi-based therapeutics that 
target disease causing genes. The RNAi pathway may be activated by exogenously supplied 
synthetic or expressed RNAi activators. Synthetic small interfering RNAs (siRNAs) mimic mature 
endogenous miRNAs whereas the expressed RNAi intermediates are derived from exogenous 
DNA templates and they mimic pri-/pre-miRNA of the RNAi pathway [Reviewed in (Mowa et al., 
2010)].  
 
An advantage of using siRNAs includes easier dose regulation and easy chemical modifications to 
reduce immune stimulation, off targeting effects and improve stability (Robbins et al., 2009). 
Chemicals such as 2’-fluoro, 2’-O-methyl and 2’-de-oxy sugars, phosphorothioate linkages have 
been used to modify siRNAs. siRNAs modified with these chemicals improved the stability of 
siRNAs and showed effective HBV silencing in cultured cells (Morrissey et al., 2005). However, 
siRNA application in gene therapy against chronic diseases like hepatitis B is limited by their short 
term effects and the requirement of a repeated administration for sustained therapeutic effects. 
 
Expressed RNAi activators are best suited for treating chronic infection with HBV as they are easy 
to propagate and are more stable with sustained efficacy as they are continuously produced from 
a stable DNA template. Most antiviral expression cassettes that have been used in RNAi 
therapeutics to inhibit HBV replication contain Pol III promoters such as U6 and H1 promoters 
with pre-miRNA mimics. Pol III promoter derived pre-miRNA mimics have been shown to 
effectively silence HBV replication. Previous studies used adeno-associated vector serotype 8 
(AAV8) to express pre-miRNA mimics (short hairpin RNAs, shRNAs) from human U6 or H1 
promoters. Complete liver transduction was observed and shRNAs were effectively expressed in 
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the liver. These shRNAs were also able to inhibit HBV replication in Huh 7 liver-derived cells as 
well as in HBV transgenic mice. U6-promoter driven shRNA however had a less sustained 
suppression effect as serum HBV DNA levels increased after two weeks. Severe liver damage was 
also observed following high dose injection of the shRNAs expressing AAVs. The shRNAs toxic 
effects resulted in mice weight loss and hepatic necrosis was induced along with elevated serum 
ALT activity. These studies also showed that these toxic effects were as a result of over expression 
of RNAi effectors from Pol III U6 or H1 promoters which saturate the endogenous RNAi pathway 
(Sun et al., 2013, Grimm et al., 2006). As a result of these limitations, expression of shRNA from 
a Pol II liver-specific ApoE/hAAT promoter was assessed and compared to that from U6 promoter. 
As expected, expression of shRNA from U6 promoter was detected in spleen, kidney and the heart, 
whereas expression of shRNA from ApoE/hAAT was only detected in the liver. Toxicity was also 
assessed by measuring ALT levels post injection. In mice injected with shRNA expressed from 
the U6 promoter, elevated levels of ALT were observed and the mice died after 3 weeks of 
injection. On the other hand, in mice injected with shRNA expressed from the ApoE/hAAT 
promoter, stable and low ALT levels were observed throughout the 96 day period of the 
measurement. Results obtained in this study therefore show that Pol II promoters offer tissue 
specificity with minimal or diminished toxicity (Giering et al., 2008) . 
To further exploit the use of tissue specific Pol II promoters, pri-miRNA mimics which are more 
compatible with Pol II promoters have been widely used. A study by (Yang et al., 2010) used 
miRNA-17-92 cluster to generate a polycistronic pri-miRNA that is processed into 5 mature 
miRNA strands that target various regions of the hepatitis C virus (HCV) genome.  A liver specific 
Pol II promoter was used and to deliver this miRNA cluster, a self-complementary AAV (scAAV) 
vector was used. All anti-HCV pri-miRNAs expression cassettes were efficiently delivered to the 
liver and resulted in gene silencing in vitro and in vivo without inducing toxicity. Previous studies 
in our lab have also generated cytomegalovirus (CMV) promoter cassettes transcribing mimics of 
naturally occurring pri-miRNA-122 (pri-miRNA 122/5) and pri-miRNA-31 (pri-miRNA31/5 or 
polycistronic pri-miRNA31/5-8/9) against HBV (Ely et al., 2009). These pri-miRNA mimics were 
able to be expressed and processed to form mature miRNAs of 21 nucleotides and suppress HBV 
replication significantly (Ely et al., 2008, Ely et al., 2009). In a study by (Mowa et al., 2014), 
murine transthyretin receptor (MTTR) liver-specific promoter driven pri-miRNAs were used to 
inhibit hepatitis B virus replication. Results obtained from this study showed that the MTTR 
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promoter results in a prolonged pri-miRNA expression in mice relative to the CMV promoter 
(Mowa et al., 2014).  Hence this study further investigated the use of MTTR promoter for anti-
HBV RNAi activator expression.  
Despite the availability of highly effective anti-HBV RNAi activators, finding the effective and 
the safest delivery system remains a daunting obstacle to progression of these sequences in to the 
clinic. For successful gene silencing, RNAi activators need to be safely and efficiently delivered 
to the target cell. To accomplish this, various methods such as viral vectors (VVs) and non-viral 
vectors (NVVs) have been explored. 
1.3 Vectors for HBV gene silencers 
1.3.1 Non-viral vectors (NVVs) 
NVVs are easy and not costly to produce in large amounts therefore making them preferred 
alternatives for gene delivery [Reviewed in (Mali, 2013)]. NVVs systems include either chemical 
methods such as liposomes and polymers, or physical methods such as naked DNA electroporation 
and hydrodynamic injection. When liposome or polymers interact with nucleic acids, they results 
in the formation of lipoplexes or polyplexes. These mask the negative charge of DNA and 
condense DNA molecules into smaller structures to facilitate interaction with the cell membrane 
for nucleic acid delivery. Liposomes can be made up of cationic lipids and neutral lipids also 
known as helper lipids. Cationic lipids are composed of both hydrophobic and hydrophilic regions 
and, positive polar heads containing hydrophobic groups [Reviewed in (Sunbul, 2014)]. 
Advantages of liposomes include low toxicity, targeted delivery and ability to incorporate 
hydrophilic and hydrophobic drugs (Ziady et al., 1999, Hofland et al., 2002, Son et al., 2000, 
Mastrobattista et al., 2002). A study by (Hean et al., 2010) used lipoplexes containing altritol 
nucleic acids- (ANAs) modified siRNAs. These ANA siRNAs resulted in inhibition of HBV 
replication of about 50 % without an induction of toxicity or immunostimulation. Even though 
lipoplexes have shown promising results, their downfall is their rapid degradation and inability to 
achieve drug delivery over a prolonged period of time (Son et al., 2000). 
Cationic polymers differ from liposomes as they do not have any hydrophobic groups, thus making 
them completely soluble in water (Elouahabi and Ruysschaert, 2005, De Smedt et al., 2000). The 
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most commonly used cationic polymers are polyethyleneimine (PEI), poly-L-(lysine) (PLL) and 
polyamidoamine (PAMAM). PEI is frequently used for in vitro gene delivery, however it is not 
biodegradable and due to it being highly positively charged, it results in dose dependent toxicity 
(Fischer et al., 1999, Gosselin et al., 2001).  
Physical methods for gene delivery have an advantage of achieving direct nucleic acid delivery 
into cells [Reviewed in (Mehier-Humbert and Guy, 2005)]. Most commonly used methods include 
electroporation and hydrodynamic injection. Electroporation entails firstly injecting DNA to target 
tissue then applying electric pulses and voltage. This technique is efficient; however it results in a 
lot of cell death and has limitations in in vivo safety. Hydrodynamic tail vein injection is a 
commonly used technique for delivering genetic material into the liver of small animals. It does 
so by using rapid, large volume intravascular injection of liquid in to the vein. This induce high 
intravascular pressure, resulting in liver size increase and concomitant nucleic acid delivery in to 
the permeabilised cells [Reviewed in (Al-Dosari and Gao, 2009)]. RNAi activators delivered via 
hydrodynamic tail injection into BV transgenic mice efficiently transduced the liver and resulted 
in significant knockdown of HBsAg expression at 3 and 5 days post injection (Ely et al., 2009). 
Even though electroporation and hydrodynamic injection have been widely used as delivery 
techniques, they are not suited to deliver HBV-targeting RNAi therapeutics.  
Even though non-viral vectors have their own advantages, the delivered nucleic acids are exposed 
to mononuclear phagocyte system clearance and prone to degradation by nucleases (Mehier-
Humbert and Guy, 2005). They are also not suitable for large expressed RNAi activator cassettes. 
 
1.3.2 Viral vectors (VVs) 
Viral vectors are highly efficient and are more compatible with antiviral RNAi expression 
cassettes. The commonly used viral vectors to deliver anti-HBV RNAi effector sequences are 
adeno-associated viruses, lentiviral vectors and adenoviruses (Park et al., 2000).  
1.3.2.1 Adeno-associated viral vectors (AAVs) 
AAVs are small, non-enveloped viruses that belong to the Parvaviridae family and the 
Dependoviridae genus. These viruses have a linear single stranded genome of 4.7 kb [Reviewed 
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in (Goncalves, 2005)]. AAVs have been used with great success in gene therapy mainly because 
they have a sustained transgene expression and are not pathogenic. In addition, following infection, 
AAVs require a helper-virus (herpesvirus or adenovirus) to replicate [Reviewed in (Daya and 
Berns, 2008)]. Thus far 12 AAV serotypes (AAV1-AAV12) and more than 100 non-human and 
human primate AAV variants have been discovered (Lisowski et al., 2014). Various studies have 
developed RNAi and AAV based gene therapeutics to treat chronic HBV infection. Three 
hepatotropic double stranded (ds) AAV vectors, dsAAV7, dsAAV8 and sdAAV9 were used and 
their transduction efficiency in vivo and their ability to inhibit HBV gene expression and 
replication were compared. These AAVs were able to deliver shRNAs to the liver efficiently and 
resulted in suppression of serum and liver HBV gene expression (Chen et al., 2009). Various 
studies have showed that by using AAVs as delivery vectors, inhibition of HBV replication is 
possible, however as high doses are usually required, a study by (Grimm et al., 2006) showed that 
this is associated with the over saturation of the endogenous RNAi pathway. Other limitations of 
AAVs include decreased delivery efficiency due to the high prevalence anti-AAV neutralizing 
antibodies in the majority of the human population and their limited transgene capacity of ~ 4.5 
kb [Reviewed in (Santiago-Ortiz and Schaffer, 2016)]. 
1.3.2.2 Lentiviral vectors (LVs) 
 LVs are derived from human immunodeficiency virus-1 (HIV-1) (Delenda, 2004) and they are 
single-stranded RNA viruses that belong to the Retroviridae family. These viruses replicate by 
reverse transcribing viral RNA genome into DNA before integration into the host genome 
[Reviewed in (Parr-Brownlie et al., 2015)]. LVs have an advantage of being able to transduce both 
diving and non-diving cells and they can be generated in high amounts (Naldini et al., 1996, 
Montini et al., 2009). In a study by Ivacik, self-inactivating (SIN) LVs expressing artificial HBV-
silencing primary microRNAs (pri-miRNAs) from a liver specific MTTR promoter were 
generated. Anti-HBV sequences were efficiently processed into mature miRNAs in liver-derived 
Huh 7 cells and resulted in significant knockdown of HBV gene expression. Expression from the 
MTTR promoter lasted for over a period of 12 months in livers of HBV transgenic mice without 
evidence of toxicity. However, the major concern with using LVs is their ability to integrate in to 
the host genome. While this result in a prolonged transgene expression, it may also result in an 
undesired essential genes inactivation or oncogene activation (Ivacik et al., 2015).  
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1.3.2.3 Adenoviral vectors (Ads) 
As a result of their natural liver tropism, non-integrative genomes, larger transgene capacity and 
prolonged transgene expression, Ads are more relevant for development of nucleic acid 
therapeutics against chronic HBV infection. Adenoviruses belong to the Adenoviridae family; they 
are non-enveloped and have icosahedral capsids which contain a linear double-stranded DNA 
genome of ~ 30-40 kb. Within the capsid there are 240 homotrimeric proteins as well as 12 
pentameric located at each of the apices of the capsid, whereas the homotrimeric fibre monomers 
extend from the penton base [Reviewed in (Mowa et al., 2010)]. There are ~50 human adenovirus 
(Ad) serotypes and six subgroups (A-F). Serotypes 2 (Ad2) and 5 (Ad5) of sub-group C are the 
most extensively studied and have been used to develop vectors for gene transfer. Ad2 and Ad5 
genome is a 36-kb linear dsDNA with inverted terminal repeats (ITRs) at each end. ITRs are 
sequences required in cis for viral DNA replication and located near the left ITR is a cis-acting 
packaging signal, which is required for genome encapsidation. The Ad genome is separated into 
three transcriptional units based on the stage at which they are transcribed during replication. These 
are the early, delayed early and the late transcriptional units. The early transcriptional unit encode 
the E1A, E1B, E2, E3 and E4 proteins. The delayed early transcriptional unit encode the proteins 
IX and IVa, as well as VA RNA I and II. The late transcriptional unit, encode L1 to L5 proteins. 
[Figure 1.5, Reviewed in (Ng and Graham, 2002, Ng et al., 2002)]. 
E1A and E1B early genes are essential and important for transcriptional regulation. They interact 
with tumour suppressor proteins Rb (retinoblastoma protein) and p53 to prevent or inhibit cell 
cycle progression and programmed cell death while permitting establishment of viral replication 
(Miller et al., 2007). Proteins required for viral DNA replication are encoded for by E2 region. The 
E3 region encodes at least seven proteins, which play a role in host immune evasion, and this 
region is unnecessary for viral growth in cell culture. On the other hand, the E4 region encodes at 
least six proteins, which aid in DNA replication, enhancement of late gene expression and decrease 
host protein synthesis. The IX protein is encoded by a gene that is collinear with E1B region, 
however their promoters differ. The VA RNA genes are produced by RNA polymerase III during 
infection, and protect cells from the antiviral response as a result of interferon-α. Late region 
transcripts are expressed from a major late promoter (MLP) as one transcript that is later processed 
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by alternative splicing to produce multiple mRNAs that mainly encode virion structural proteins 
[L1-L5, Reviewed in (Brunetti-Pierri and Ng, 2013, Ng et al., 2002, Punga et al., 2013)]. 
 
Figure 1.4: Map of wild-type adenovirus serotype 5 genome. Blue boxes at the end represent 
inverted terminal repeats (ITRs), ψ indicates the packaging signal and the orange box represents 
the major late promoter (MLP). E1-E4 represents the early genes, whereas L1-L5 shows the late 
transcripts. The arrows indicate direction of the transcription. Image adapted from (Palmer and 
Ng, 2008a). 
 
Recombinant adenoviral vectors are the most commonly used delivery vehicles in gene therapy 
because they are able to transduce both dividing and non-dividing cells, have the ability to 
accommodate large DNA inserts, and they are easy to produce in high titres. In addition, a well-
established biology of Adenoviruses makes it easy for the viruses to be manipulated for therapeutic 
purposes (Kreppel and Kochanek, 2008, Wonganan and Croyle, 2010). 
Development of adenoviruses as gene therapy vectors is well advanced and there are mainly three 
types of adenoviral vectors generated: first-generation, second-generation and third-generation 
(Figure 1.5). First-generation adenoviruses have been widely applied in gene therapy for many 
years; these vectors do not have the viral E1 gene making them replication defective. In addition 
to E1 deletion some first generation vectors have E3 deleted (Ndi et al., 2013). U6 promoter 
shRNA cassettes against HBV have been previously delivered using 1st generation adenoviral 
vectors. These shRNAs were efficiently processed; shRNA5 and shRNA6 resulted in ̴ 80-100 % 
knockdown of HBV replication in vitro and in vivo. Even though these expression cassettes 
showed effective HBV inhibition, adenoviral gene expression from these vectors triggered a 
strong, vector dose dependant immune response (Crowther et al., 2008). Other studies have also 
showed that expression of adenoviral genes in these vectors triggers cytotoxic T lymphocyte (CTL) 
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immune response towards infected cells, resulting in the elimination of transduced cells and loss 
of therapeutic gene expression (Alba et al., 2005, Parks et al., 1996). 
To overcome these limitations, second-generation adenoviral vectors were developed. In addition 
to E1 and E3 deletion, these vectors have the E2/ E4 genes removed, which reduces 
immunostimulatory effects; prolongs transgene expression and increases vector cloning capacity 
[Reviewed in (Kreppel and Kochanek, 2008)]. Various studies have used second-generation 
adenoviral vectors in gene therapy. Adenoviral vectors with E1 and E4 deletions and expressing 
β-galactosidase were constructed and these resulted in ̴ 80 % liver transduction and expression of 
β-galactosidase for up to 3 months in mice. Compared to first-generation, second-generation 
adenoviral vectors showed reduced cytopathic effect, resulted in prolonged transgene expression 
in vivo with minimal virus-specific immune response (Wang et al., 1997). A study described results 
of a phase I clinical trial of an E1 and E4-deleted adenovirus vector administered into the right 
hepatic artery of people with partial ornithine transcarbamylase deficiency (OTCD). Eighteen 
people were chosen to be subjects of the study and they were receiving alternate pathway therapy 
(sodium phenylbutyrate and citrulline/arginine) for OTCD during this study. Each subject received 
a single dose of E1 and E4-deleted adenoviral vector containing human OTC cDNA. The vector 
was infused into the right hepatic artery by using a catheter placed under fluoroscopic guidance. 
Following vector delivery, increase in temperature, hepatic transaminases, thrombocytopenia and 
hypophosphatemia were observed in all the subjects. Very toxic effects were also observed which 
resulted in the death of subject 18. Findings obtained in this study therefore showed that residual 
viral gene expression in second-generation adenoviral vectors results in vivo-associated 
immunogenicity and toxicity (Raper et al., 2002). As a result, third-generation vectors also called 
gutless vectors have been generated. These vectors are also called helper-dependent adenoviral 
vectors (HDAds) as a result of the fact that they require a helper adenovirus (HV) to replicate. 
They are also referred to as high-capacity adenoviruses since they can accommodate up to ~37 kb 
of DNA. HDAds have all their viral coding sequences removed and only retain the ITRs required 
for DNA replication as well as the packaging signal (ψ) required for DNA encapsidation (Alba et 
al., 2005). 
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Figure 1.5: First-, second-, and third-generation Ad vectors. First-generation vectors are 
devoid of E1 only, which is usually replaced by a transgene, or E1 and E3 deleted, second-
generation vectors are devoid of E1 and E3 and additionally have E2/E4 deletion, whereas third-
generation or HD adenoviral vectors have all the viral sequences deleted. This vector contains the 
5’ and 3’ inverted terminal repeats (ITRs), the packaging signal (ψ), transgene, and a stuffer DNA 
which is there to adjust the genome size so that it is more or less the same as the wild type genome. 
Δ: shows deletion mutation and the purple colour shows the remaining adenoviral sequence. Image 
adapted from (Palmer and Ng, 2008a). 
 
Because of their significantly reduced immune stimulation and in vivo long-term transgene 
expression with insignificant toxicity, HDAds are appropriate for use in gene therapy (Alba et al., 
2005, Suzuki et al., 2010). To produce HDAds, a helper virus (HV) is required to complement for 
adenoviral genes required for viral production and amplification. Graham and co-workers 
developed the first competent and most reliable HV system for the generation of HDAds 
commonly used today in gene therapy. This uses the Cre/loxP system, where E1 and Cre-
expressing 293 cells (293Cre) are transfected with HDAd genome and infected with the first 
generation adenoviral vector which carries a packaging signal flanked by loxP sites. In this system, 
HV genome is unpackageable as a result of Cre-mediated packaging signal excision (Figure 1.6). 
Sequential co-infection of 293Cre cells with HDAds and HV result in selective packaging of 
HDAd genome and increases HDAd titer which is further purified by caesium chloride (CsCl) 
ultracentrifugation (Palmer and Ng, 2003b).   
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Figure 1.6: Propagation of HDAds. For production of HDAd, Cre recombinase and E1 
expressing cell line (293cre) is transfected with HDAd genome and infected with HV. This results 
in homologous recombination of the HV loxP sites and excision of the packaging signal. The 
excision of this packaging signal makes the HV genome unpackagable and results in selective 
packaging of the HDAd genome. Image adapted from (Palmer and Ng, 2008b). 
 
1.4 Application of HDAds for development of antiviral RNAi based 
therapy 
For a delivery vector to be considered for therapeutic use, it needs to be safe, offer prolonged 
transgene expression with no induction of immune response. HDAds have been the vector of 
choice for various studies in gene therapy and have shown tremendous therapeutic potential. 
Vectors containing apolipoprotein (apo) E gene were constructed, these vectors were: i) FG-Ad5-
cE which is a serotype-5 first-generation adenoviral vector containing apoE complementary DNA 
(cDNA) driven by a cytomegalovirus (CMV) promoter; ii) HD-Ad-cE, a helper-dependent 
adenoviral vector expressing apoE cDNA from a phosphoenolpyruvate carboxykinase (PEPCK) 
promoter; iii) HD-Ad-gE, a helper-dependent adenoviral vector expressing native apoE gene with 
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a liver-specific enhancer at the 3’ end; and iv) HD-Ad-0, an empty helper-dependent adenoviral 
vector without any transgene. A single dose of the different vectors was injected via the tail vein 
of the 12-14 week-old apoE deficient hypercholesterolemic mice. All the apoE-Ads besides the 
empty vector resulted in a decrease in plasma cholesterol levels; however the effect of FG-Ad5-
cE was short-lived as the plasma cholesterol levels returned to control levels after 28 days and 
were undetectable at day 140. Contrary to this, HD-Ad5-gE treated mice had sustained levels of 
plasma apoE similar to wild type for > 4 months, whereas HD-Ad5-cE had normal plasma 
cholesterol levels for about a year.  A drastic decrease in plasma cholesterol without any signs of 
toxicity was also observed for HD-Ad5-cE and HD-Ad5-gE vectors, whereas FG-Ad5-cE induced 
an elevation in liver enzymes (Kim et al., 2001). Application of HDAds in RNAi-based 
therapeutics has shown great successes. First studies to demonstrate the use HDAds against HBV 
expressed IFN-α or IL-12 in a woodchuck or mouse model of acute or chronic hepatitis B.  This 
resulted in specific intrahepatic expression of transgenes and sustained anti-HBV effects (Crettaz 
et al., 2009, Aurisicchio et al., 2000).  Rauschhuber and co-workers used HDAds to deliver shRNA 
coding sequences expressed from the U6 promoter into HBV transgenic mice. An HDAd vector 
expressing β-galactosidase was used as a control. The transduction efficiency was 100 % three 
days post injection in hepatocytes. The shRNAs were also efficiently processed into the mature 
intended guide strands and resulted in about 68 % decrease in HBsAg levels in vitro and in vivo 
respectively. Surprisingly, the control vector resulted in 86 % decrease in HBsAg levels. Mice 
treated with the control vector (HD28E4lacZ) had elevated transaminase levels; this was assumed 
to be a result of immune response against β-galactosidase (Rauschhuber et al., 2008). 
In a study by (Crowther et al., 2014) HDAds were used to deliver shRNAs under the control of a 
Pol III promoter. On the other hand,  (Mowa et al., 2012) produced HDAds expressing pri-miRNA 
mimics also under the control of the Pol II CMV promoter. HDAds used in these studies were able 
to efficiently deliver anti-HBV RNAi activators to the hepatocytes and resulted in pri-miRNA 
expression and processing into mature guide strands.  These HDAds also resulted in significant 
knockdown of HBV replication in liver-derived Huh 7 cells as well as in HBV transgenic mice. 
The only downfall about these HDAds was that they resulted in a short term transgene expression 
and anti-HBV effects. And this was attributed to the use of non-liver specific promoters that may 
be silenced in the liver. To allow for tissue-specific expression and prolong anti-HBV effects 
HDAds expressing pri-miRNA mimics from the liver-specific MTTR promoter were produced.  
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The anti-HBV pri-miRNAs were efficiently delivered in vitro and in vivo thereby may result in 
significant knockdown of HBV replication and prolonged transgene expression compared to CMV 
promoter expressed pri-miRNAs (Mowa et al., 2014). 
Even though HDAds have all the adenoviral genes deleted, showed improved safety profile and 
are more effective than their counterparts, immunostimulatory effect from capsid proteins and 
sometimes from transgene encoded proteins is still a challenge. 
  
1.4.1 Reducing immune stimulation by the capsid proteins  
Shielding epitopes on the capsids by chemical modifications using polymers such as polyethylene 
glycol (PEG) have been shown by several studies to reduce non-specific interactions with non-
target sites which may results in the induction of the immune response and elevated toxicity 
(Kreppel et al., 2005). PEG is a chemically inert compound consisting of either linear or branched 
repeat units of ethylene oxide. The covalent attachment of PEG to molecules is known as 
PEGylation and this technique has been employed to improve the stability, solubility and 
immunological properties of many biological compounds such as lipids, cells, viruses etc. 
(Wonganan and Croyle, 2010).  
As a result of hydroxyl (-OH) groups, which are unable to react with the proteins, PEG molecules 
require activation before they can be coupled to proteins. This is achieved by substituting the single 
–OH group at the end of the PEG molecule with an electrophilic reactive group that can be 
covalently linked to the reactive site of the molecule of interest (Wonganan and Croyle, 2010). 
Target sites normally used for protein PEGylation are the epsilon-amino groups of lysine residues, 
N-terminus of the protein or thiol groups of cysteine residues. The surface of Ad vector capsid is 
dominated by the amine functional groups resulting in approximately 18 000 amine groups on 
human Ad5. N-hydroxysuccinimide (NHS) esters are activation groups required for amine 
PEGylation. Maleimide or dithiopyridyl are activation groups required for thiol PEGylation 
(Kreppel and Kochanek, 2008). 
Monomethoxy polyethylene glycol-succinimidyl propionate (mPEG-SPA) was used to alter anti-
HBV RNAi effector expressing first-generation vectors. From this study, PEG-modified vectors 
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resulted in a decrease in intrahepatic HBV mRNA and HBV viral particle equivalents (VPEs) 
following the first Ad injection. Following injection of PEGylated and unPEGylated Ad, serum 
levels of monocyte chemoattractant protein-1 (MCP-1, marker of inflammation) were elevated in 
mice which received unPEGylated vector (Crowther et al., 2008). Even though the amine 
PEGylation used in this study was able to reduce immunostimulation, studies have shown that this 
PEGylation method reduce Ad transduction efficiency (Kreppel and Kochanek, 2008). 
To allow efficient thiol dependent PEGylation of Ad vectors, a helper-virus (HV) carrying a gene 
encoding the hypervariable hexon region of the capsid with a cysteine modification was developed. 
The HV (AdNG163cys) was generated by introducing a single point mutation into the 
hypervariable region 5 (HVR5) hexon of AdNG163 (with wild type HVR 5), where alanine was 
substituted by a cysteine residue. Ads produced using AdNG163cys were reacted with maleimide-
activated PEG (mal-PEG) molecules of various sizes. After performing Western transfer and 
immunochemical detections with an anti-hexon antibody, 50-70 % of the hexon monomers were 
efficiently modified. It was also found out that cysteine modification does not alter vector tropism 
but rather increases the liver transduction efficiency (Prill et al., 2011). Hence, the application of 
HDAds with cysteine modification for anti-HBV RNAi effector delivery was investigated in this 
study. 
 
1.4.2 Reducing the immune stimulation by transgene encoded proteins. 
For a delivery vector to be regarded effective, it must be able to deliver efficiently the therapeutic 
to the target cells. The common way of checking for the efficiency of gene transfer or delivery is 
through the use of reporter genes. Lac Z which encodes for β-galactosidase is the commonly used 
reporter gene in gene delivery, mainly because of its ease of detection in vitro and in vivo (Naderian 
et al., 2011). In the various studies that have investigated the association of β-galactosidase and 
induction of immune response, common observations were that in the presence of β-galctosidase 
transgene expression is shortened and results in vector clearance (Chen et al., 1997, Morral et al., 
1997, Sullivan et al., 1997). Elevation of β-galactosidase specific antibodies and short-term 
inhibition of HBV replication was also observed in a study where β-galactosidase was co-delivered 
with anti-HBV RNAi activator sequences (Crowther et al., 2014). To avoid such limiting results, 
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lacZ deficient HDAds expressing pri-miRNA mimics from a liver-specific promoter were 
produced in this study. 
 
1.5 Aim and objectives 
The aim of this study was to produce and characterize lac Z deficient recombinant HDAds 
expressing anti-HBV pri-miRNA sequences from MTTR liver-specific promoter. To achieve this 
aim the following objectives were set.  
 
 Objectives 
1. Construction of adenoviral plasmids expressing anti-HBV pri-miRNAs from MTTR 
promoter. 
2. Production, amplification and purification of anti-HBV helper-dependant adenoviral 
vectors using unmodified and cysteine modified helper virus 
3. Measurement of in vitro pri-miRNA expression in HDAds infected cell line and in mice 
using Northern blot hybridization 
4. Assessment of HBV knockdown in vitro and in vivo using ELISA. 
5. Measurement of inflammatory cytokines in mice by using cytometric bead array (CBA). 
6. Assessment of HDAd-induced liver toxicity by measuring serum alanine aminotransferase 
(ALT) levels. 
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CHAPTER 2 
2. MATERIALS AND METHODS 
2.1 Bacterial culturing, storage and manipulations 
2.1.1 Culturing of E.coli cells  
Xl-Blue and DH5α Escherichia coli (E. coli, Table 2.1) cells were grown in Luria Bertani media 
(LB, Appendix 7.1.1) or Luria Bertani agar media (LA, Appendix 7.1.2) at 37 °C. To grow strains 
carrying antibiotic resistance marker, media was supplemented with 100 µg/mL or 50 µg/mL of 
ampicillin (Appendix 7.1.3) or kanamycin (Appendix 7.1.4) respectively. The liquid cultures were 
incubated shaking at 100-150 g.  All freezer stocks were frozen in 25 % glycerol at -80 oC. Table 
2.1 shows the E.coli strains used in this study along with their genotypes. 
Table 2.1 Table of E.coli strains used in this study 
Bacterial strain Genotype Company/ Reference 
Xl-Blue cells F- φ80lacZ∆M15 
∆(lacZYA-argF)U169 
recA1 endA1 hsdR17(rk - , 
mk +) phoA supE44 thi-1 
gyrA96 relA1 λ- 
Thermo Fischer Scientific, 
MA,USA                  
DH5α cells fhuA2 Δ(argF-lacZ)U169 
phoA glnV44 ɸ80Δ (lacZ) 
M15 gyrA96 recA1 relA1 
endA1 thi-1 hsdR17 
New England Biolabs®Inc, 
MA, USA 
 
 
2.1.2 Preparation of chemically competent Xl-Blue cells 
Xl-Blue cells from a freezer stock (2 µl) or from a single colony were inoculated in 10 mL of LB 
media (Appendix 7.1.1). The bacterial culture was incubated overnight at 37 °C with shaking at 
100 – 150 rpm. The pre-culture was diluted 100× in LB media (Appendix 7.1.1) and incubated at 
37 °C with shaking at 200 – 250 rpm. The optical density (OD) was measured until the absorbance 
reading at 600 nm was between 0.4 – 0.6. The cultures were poured into 50 mL Falcon tubes and 
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centrifuged at 6000 g for 20 minutes at 4 °C. The supernatant was discarded; the pellet was re-
suspended in 10 mL of the transformation buffer (Appendix 7.1.6) and incubated on ice for 20 
minutes. The cells were centrifuged at 6000 g for 15 minutes, the supernatant was discarded and 
the pellet was re-suspended in 1 mL of the transformation buffer (Appendix 7.1.6). Aliquots of 
100 µl were transferred into sterile micro-centrifuge tubes and stored at -80 °C. 
 
2.1.3 Transformation of chemically competent Xl-Blue cells 
Chemically competent Xl-blue cells (100 µl) were added to a pre-chilled DNA. The mixture was 
incubated on ice for 10 minutes then heat shocked on a heating block at 42 °C for 90 seconds. 
Immediately after heat shock, 500 µl of pre- warmed LB (Appendix 7.1.1) was added to the 
mixture and incubated for an hour at 37 °C with shaking for phenotypic expression. The entire 
volume was plated on pre-warmed LB agar plates (Appendix 7.1.5) supplemented with the relevant 
antibiotic. The plates were allowed to dry at 37 °C and placed upside down in the incubator at 37 
°C overnight.  
 
2.1.4 Transformation of DH5α electro-competent cells 
About 50 µl of electro competent DH5α cells (New England Biolabs, MA, USA) was added to 
pre-chilled DNA. The mixture was incubated for 10 min on ice and transferred into 2 mm 
electroporation cuvettes. The electroporation conditions were set on the Biorad Gene Pulsar 
XcellTM Electroporation system as follows: voltage: 2000V, capacitance: 25F and resistance: 200 
Ω. The samples were electroporated by pressing pulse and 1 mL of pre-warmed rescue C-media 
(Thermo Fisher Scientific, MA, USA) was immediately added into the cuvettes. Cells were 
transferred into 2 mL micro centrifuge tubes, incubated for 1 hr at 37 °C with shaking at 150 rpm. 
Cells were plated on LB agar plates (Appendix 7.1.5) supplemented with the appropriate antibiotic. 
The plates were allowed to dry at 37 °C and placed upside down in the incubator at 37 °C overnight. 
 
2.2 Plasmid DNA preparation and purification 
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2.2.1 Small scale plasmid DNA isolation by alkaline lysis 
A single colony containing the plasmid of interest was inoculated in 2 mL of LB (Appendix 7.1.1) 
media supplemented with the appropriate antibiotic and incubated overnight with shaking at 37 
°C. The bacterial cultures were then transferred into sterile 2 mL micro-centrifuge tubes and 
centrifuged for 30 seconds at maximum speed to pellet the bacteria. The pellet was re-suspended 
in 180 µl of buffer P1 (Appendix 7.2.1) and 160 of Buffer P2 (Appendix 7.2.2) was added to the 
cells. To allow cell lysis, the mixture was gently inverted and incubated at room temperature for 5 
minutes. Buffer P3 (120 µl, Appendix 7.2.3) was added to neutralise the solution and mixed 
thoroughly by flicking the tube and incubated on ice for 5 minutes. This was centrifuged for 10 
minutes at maximum speed at 4 °C. The supernatant was transferred to a new sterile micro-
centrifuge tube and the DNA was precipitated by adding 600 µl of 100 % isopropanol (Merck 
Chemicals (Pty) Ltd, Darmstadt, Germany). This was inverted to mix, incubated at room 
temperature for 2 minutes and centrifuged at maximum speed for 20 minutes. The pellet was 
washed with 150 µl of 70 % ethanol (Merck Chemicals (Pty) Ltd, Darmstadt, Germany), 
centrifuged at maximum speed for 2 minutes at 4 °C and air-dried for 10 minutes at room 
temperature. DNA was re-suspended in 50 µl of sterile double deionised water (ddH2O) and 
concentration determined using the Nano-drop spectrophotometer at OD260. 
 
2.2.2 Large scale Plasmid DNA isolation 
2.2.2.1 Plasmid DNA isolation by QIAGEN Plasmid Maxi Kit 
Large scale plasmid DNA preparation and purification was performed using Qiagen Plasmid Maxi 
Kit (Qiagen, MD, USA) according to manufacturer’s instructions. Briefly, a single colony with 
the plasmid of interest was inoculated in 100 mL of LB (Appendix 7.1.1) media supplemented 
with the appropriate antibiotic and incubated overnight at 37 °C with shaking at 150 rpm. The 
bacterial cells were harvested by centrifugation at 6000 g for 15 minutes at 4 °C. The bacterial 
pellet was re-suspended in 10 mL of chilled buffer P1 (Appendix 7.2.1), 10 mL of buffer P2 
(Appendix 7.2.2) was subsequently added and the samples were mixed by inverting the tube then 
incubated at room temperature for 5 minutes. Ten millilitres of chilled buffer P3 (Appendix 7.2.3) 
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was added; samples were mixed by inverting the tube and incubated on ice for 15 minutes. The 
solution was centrifuged at 20 000 g for 30 minutes at 4 °C. During centrifugation step Qiagen-tip 
500 was equilibrated by applying 10 mL of QBT buffer and the column was allowed to empty by 
gravity flow. The supernatant from the centrifuged sample was applied to the Qiagen-tip 500 and 
allowed to enter the resin by gravity flow. Qiagen-tip 500 was washed twice with 30 mL of QC 
buffer and placed in a 50 mL Falcon tube. The DNA was eluted with 15 mL of QF buffer and 
precipitated by adding 10.5 mL of room temperature isopropanol (Merck Chemicals (Pty) Ltd, 
Darmstadt, Germany). The solution was mixed and centrifuged at 15 000 g for 30 minutes at 4 °C. 
The supernatant was carefully removed, the pellet was washed with 500 µl of ice cold 70 % ethanol 
(Merck Chemicals (Pty) Ltd, Darmstadt, Germany) and centrifuged at 15 000 g for 10 minutes at 
4 °C. The supernatant was carefully removed, the pellet was air-dried for 10 minutes and the DNA 
was re-dissolved in 500 µl of sterile dH2O. The concentration of the plasmid DNA was measured 
on the Nano-drop Spectrophotometer. 
 
2.2.2.2 Plasmid DNA isolation by Genopure Plasmid Maxi Kit 
Plasmid DNA used for the generation of recombinant HDAd in tissue culture was purified using 
Genopure Plasmid Maxi Kit (Roche Diagnostics, GmbH, Germany), following the manufacturer’s 
instructions with minor modifications. Briefly, a single colony with the plasmid of interest was 
inoculated in 100 mL of LB (Appendix 7.1.1) media supplemented with the appropriate antibiotic 
and incubated overnight at 37 °C with shaking at 200-250 rpm. The bacterial cells were centrifuged 
for 30 minutes at 5000 g and the pellet was re-suspended with 8 mL suspension buffer. Twelve 
millilitres of lysis buffer was added to the suspension and incubated for 5 minutes at room 
temperature. This was followed by addition of 12 mL neutralization buffer, gentle mixing by 
inversion and incubation for 5 minutes on ice. The solution was centrifuged for 1 hour at 12 000 g 
and the lysate was loaded onto the column equilibrated with 6 mL of equilibration buffer. The 
column was allowed to empty by gravity and it was washed twice with 16 mL of wash buffer. The 
column was inserted into a new collection tube and the plasmid was eluted with 15 mL of elution 
buffer. The eluted plasmid was precipitated with 11 mL of isopropanol (Merck Chemicals (Pty) 
Ltd, Darmstadt, Germany), incubated for 30 minutes at -20 °C and centrifuged for 30 minutes at 
15 000 g. The pellet was washed with 4 mL of chilled 70 % ethanol (Merck Chemicals (Pty) Ltd, 
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Darmstadt, Germany) and centrifuged for 10 minutes at 15 000 g. The pellet was air-dried for 10 
minutes at room temperature and dissolved in 500 µl of sterile distilled water. The concentration 
of the plasmid DNA was measured on the Nano-drop –Spectrophotometer. 
 
2.3 Manipulation and analysis of DNA 
2.3.1 Restriction enzyme (RE) digestion of plasmid DNA 
Plasmid DNA isolated using the above mentioned methods was digested with the desired RE for 
the preparation of cloning vectors, extraction of inserts and screening for positive clones. All the 
solutions were thawed on ice. Digestion reactions were set up with 1-11 µg of DNA, 1× reaction 
buffer, 1-11 U enzyme (Thermo Fisher Scientific, MA, USA or New England Biolabs, MA, USA), 
dH2O to top up to the required volume and incubated overnight at 37 °C.  
 
2.3.2 Vector dephosphorylation  
Plasmid DNA was digested with the RE, which was then inactivated by heating for 20 minutes at 
65 °C.  To prevent re-circularization of the vector, the DNA was incubated with 1 U/µg of 
Antarctic Phosphatase (New England Biolabs, MA, USA) for an hour at 37 °C. The reaction was 
inactivated by heating at 75 °C for 15 minutes on a heating block.  
 
2.3.3 Quantitative Polymerase Chain Reaction (qPCR) 
Quantitative PCR (qPCR) was performed by mixing 1 µl of 10 µM forward and reverse primers 
(Table 2.2), 10 µl of 2 × concentrated FastStart Essentila DNA Green Master (Roche Diagnostics, 
GmbH, Germany), 20-100 ng of DNA and dH2O was added to top up the final volume to 20 µl in 
a PCR tube. Reactions with DNA standards were also set-up the same way in parallel. The 
reactions were put in the Bio-Rad CFX96TM Real Time System (Bio-Rad, CA, USA) machine. 
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The cycling conditions were set as shown in Table 2.3 and the reactions performed in the 
27thermos cycler. 
 
Table 2.2: Primers used in this study 
Primer  Sequence Description Reference 
HDAd F 
 
5’GAAAAAACACACTGGCTTGAAACA’3 Forward primer used for 
HDAd sequence 
amplification 
(Palmer and 
Ng, 2003a) 
HDAdR 
 
5’TGCCACCTCGTATTTCACCTCTA’3 Reverse primer for HDAd 
sequence amplification 
(Palmer and 
Ng, 2003a) 
HV F 5’ TGGGCGTGGTGCCTAAAA’3 Forward primer for helper-
virus sequence amplification  
(Palmer and 
Ng, 2003a) 
HV R  5’ GCCTGCCCCTGGCAAT’3 Reverse primer for helper-
virus sequence amplification 
(Palmer and 
Ng, 2003a) 
 
Table 2.3: Cycling conditions for PCR 
Step Temperature (°C) Time Number of 
cycles 
Initial denaturation 95 5 minutes 1 
Denaturation 98 20 seconds  
34 Primer annealing 60 30 seconds 
Extension 72 3 minute/kb 
Final extension 72 5 minutes 1 
Cooling 4 ∞ 1 
  
 
2.3.4 Ligation  
For the cloning of RE digested fragments, Fast-LinkTM DNA Ligation Kit (Epicentre 
Biotechnologies, WI, USA) was used following the manufacturer’s instructions. Ligation reactions 
were setup with the insert at a molar excess and various vector to insert ratios (1:3, 1:6, 1:12 and 
1:24) were used. The ligation reactions were set up as shown in Table 2.4 in sterile micro-
centrifuge tubes. The reactions were incubated at 4°C overnight. The ligation mixture (1 µl) was 
transformed in DH5α electro competent cells (section 2.1.4, New England Biolabs®Inc, MA, 
USA). 
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Table 2.4: Ligation reaction set up for Fast-LinkTMDNA Ligation 
Component Quantity 
10× Fast-Link Ligation Buffer 1.5 µl 
10 mM ATP 1.5 µl 
Vector DNA 1000 ng 
Insert DNA 50 – 500 ng 
Sterile Water Up to 14 µl 
Fast-Link DNA Ligase 1 µl 
 
2.3.5 Agarose gel electrophoresis 
A 1 % agarose gel was prepared by weighing 1 g of powdered agarose into a conical flask, 100 
mL of 1 × tris-acetate-EDTA (TAE, Appendix 7.2.7) electrophoresis running buffer was added 
and the solution was mixed by swirling. The agarose was melted by microwaving for 3 minutes 
and cooled to ~ 55 °C. Once the agarose has cooled down, 10 µl of 10 mg/mL ethidium bromide 
was added. The gel was poured in to the assembled casting tray. The gel was allowed to solidify, 
the comb and dams were removed from the tray and the gel was placed into the electrophoresis 
tank. TAE buffer (Appendix 7.2.7) was added to cover the wells.  Tracking dye (Thermo Fisher 
Scientific, MA, USA) was added to DNA to a final concentration of 1 ×. A DNA size molecular 
weight marker (Thermo Fisher Scientific, MA, USA) was loaded in the first and last wells, whereas 
the samples were loaded in the middle wells. The current was applied and the gel was run at 90 V 
until the tracking dye reached the bottom of the gel. 
 
2.3.6 DNA extraction from agarose gel 
2.3.6.1 Gel Extraction by QIAquick Gel extraction kit 
Plasmid DNA digested with restriction enzyme of interest was run on a 1 % agarose gel and 
fragments of interest extracted using the QIAquick®Gel Extraction Kit (Qiagen, CA, USA) 
following the manufacturer’s instructions. Briefly, the DNA fragments of interest were excised 
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from the agarose gel with a clean, sharp scalpel. The gel slices were weighed, three volumes of 
buffer QG was added (0.1g ~ 100 µl) and incubated at 50 °C for 10 minutes or until the gel slices 
had completely dissolved. Following addition of isopropanol, the samples were transferred to the 
QIAquick spin columns in a 2 mL collection tubes and centrifuged for 1 minute at maximum speed. 
The flow through was discarded and the columns were placed back in the same collection tubes.  
About 500 µl Buffer QG was added to spin columns and centrifuged for a minute at maximum 
speed. To wash the DNA sample, 500 µl buffer PE was added and spun for a minute at maximum 
speed. The spin columns were transferred to a sterile 1.5 mL micro centrifuge tube. Fifty 
microliters of sterile dH2O was added to elute the DNA from the columns. This was centrifuged 
at maximum speed for 1 minute. The concentration of the DNA was measured on the Nano-drop 
spectrophotometer and 500 -1000 ng was run on a 1 % agarose gel to confirm the correct DNA 
fragment size. 
2.3.6.2 Gel Extraction by phenol Chloroform 
The agarose gel was placed under UV light and a sharp clean scalpel was used to excise the DNA 
fragment of interest. A sterile heated needle was used to pierce a small hole at the bottom of a 
sterile 0.5 µl micro centrifuge tube and fish tank wool was placed at the bottom of tube. The gel 
pieces containing DNA fragments of interest were added to this tube, the 0.5 µl tube was placed 
inside a sterile 2 mL micro centrifuge tube. This was centrifuged at maximum speed until all the 
buffer had transferred to the 2 mL tube. Phenol and chloroform (100 µl per 300 µl buffer) at a 1:1 
ratio were added to the DNA and it was centrifuged at maximum speed for 5 minutes. The upper 
layer was removed and transferred to a new sterile micro centrifuge tube. Chloroform was added 
and the mixture was centrifuged for a minute at maximum speed. The upper layer was removed 
and transferred to a sterile micro centrifuge tube and the volume was adjusted to 300 µl with dH2O. 
Sodium acetate to a final concentration of 0.3 M (Sigma-Aldrich, MO, USA) and 2.5 × of 100 % 
ethanol (Merck Chemicals (Pty) Ltd, Darmstadt, Germany) was added. The mixture was incubated 
for 30 minutes at -20 °C. The solution was centrifuged for 30 minutes at maximum speed and the 
resultant pellet washed with 500 µl of 70 % ethanol (Merck Chemicals (Pty) Ltd, Darmstadt, 
Germany). The solution was centrifuged for 5 minutes at maximum speed and the pellet was air-
dried and re-suspended in 20 µl of sterile dH2O.The concentration of the DNA was measured on 
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the Nano-drop spectrophotometer and 500 - 1000 ng was run on a 1 % agarose gel to confirm the 
correct DNA fragment size. 
 
2.4 Construction of lac Z deficient Adenoviral plasmids 
expressing anti-HBV sequences from mouse transthyretin 
(MTTR) promoter 
Construction of required plasmids was carried according to standard cloning procedures 
described above. Table 2.5 shows all the plasmid used and constructed in this study. 
For the generation of adenoviral plasmids expressing anti-HBV pri-miRNAs from MTTR 
promoter, monomeric or trimeric pri-miRNA expression cassettes in pTZ pri-miR-31/5 or pTZ 
pri-miR-31-5-8-9 previously described by (Mowa et al., 2012) were extracted using AscI 
restriction enzyme and ligated into the lac Z deficient adenoviral genome bearing plasmid 
(pΔ28E4, kindly donated by Brendan Lee, Baylor College, USA) AscI site. 
 
 
 
 
 
 
 
 
Table 2.5 Description of plasmids used and constructed in this study 
Plasmid name Description Selection 
marker  
Reference 
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pTZMTTR-pri-mi-R-
31/5 
pTZ57R/T TA cloning 
vector carrying pri-miR-
31/5 MTTR promoter 
cassette with AscI 
engineered RE sites 
Ampicillin  (Mowa et al., 2014) 
pTZMTTR-pri-mi-R-
31/5-8-9 
pTZ57R/T TA cloning 
vector carrying pri-miR-
31/589 MTTR promoter 
cassette with AscI 
engineered RE sites 
Ampicillin (Mowa et al., 2014)  
pΔ28E4 Lac Z deficient 
Adenoviral genome 
bearing plasmid 
Kanamycin Brendan Lee, Baylor 
College, USA 
pΔ28E4CMVlacZ Adenoviral genome 
bearing plasmid 
expressing the lac Z 
reporter gene from the 
CMV promoter 
Kanamycin Phillip Ng, Baylor 
College, USA 
pHDAd-pri-miRNA-
31/5 
pΔ28E4expressing anti-
HBV pri-miRNA 31/5 
from the MTTR promoter 
Kanamycin This study 
pHDAd-pri-miRNA-
31/589 
pΔ28E4expressing anti-
HBV pri-miRNA 31/589 
from the MTTR promoter 
Kanamycin This study 
pCH-9/3091 A target plasmid with a 
greater genome length 
HBV sequence  
Ampicillin (Nassal et al., 1990) 
pCI-neo-eGFP pCI-neo mammalian 
expression vector 
expressing the enhanced 
green fluorescence 
protein (eGFP) from the 
CMV promoter 
Ampicillin (Passman et al., 2000) 
 
 
2.5 Tissue culture methods 
2.5.1 Cell culturing conditions 
Human Embryonic Kidney 293 (HEK293) and Human hepatoma (Huh7) cells were propagated in 
Gibco® Dulbecco's Modified Eagle's Medium (DMEM, Thermo Fisher Scientific, MA, USA). 
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HEK293 derived 116 cells were propagated in Eagle’s Minimum Essential Medium (EMEM, 
Thermo Fischer Scientific, MA, USA) or Joklik Eagle’s Minimum Essential Medium (JEMEM).  
DMEM media was supplemented with 10 % (W/V) fetal bovine (FBS, Thermo Fisher Scientific, 
MA, USA), 100 000 U/mL of penicillin and 100 µg/mL of streptomycin. EMEM media (Appendix 
7.3.1) was supplemented with 10 % or 5 % (W/V) Gobco® FBS (Thermo Fisher Scientific, MA, 
USA), penicillin to 100 000 U/mL, streptomycin to 100 µg/mL,  as well as Gibco® L-glutamine 
(Thermo Fisher Scientific, MA, USA) to 2 mM. JEMEM (Appendix 7.3.3) with 5 % (W/V) faecal 
calf serum (FBS, Thermo Fisher Scientific, MA, USA), 100 000 U/mL of penicillin, 100 µg/mL 
of streptomycin and 0.1 mg/mL hygromycin (Sigma-Aldrich, MO, USA) was used. All cell lines 
were maintained in humidified incubators at 37 °C and 5 % CO2.  
 
2.5.2 Seeding and growing of cells 
To grow up cells from a frozen stock, 1 mL aliquot of cells was defrosted and added to 10 mL of 
appropriate complete media (with 10 % FBS and 2 mM L-glutamine). This was spun down for 3 
minutes at 5000 g to pellet the cells. The media was carefully discarded and the pellet was re-
suspended in 2 mL of complete media, transferred into a small flask (25 cm2) with 5 mL of 
complete media. The cells were left in the humidified incubator until they were 100 % confluent. 
To subculture the cells, medium was poured off, 1mL of saline was added to wash the cells. Cells 
were incubated with 1 mL of saline supplemented with EDTA for 3 minutes at 37 °C in the 
incubator. For Huh7 cells, saline-EDTA was replaced with 500 µl of 0.5 × Gibco® TrypLE express 
(Thermo Fisher Scientific, MA, USA). The flask was tapped on the sides to detach the cells, 1mL 
of complete media (Thermo Fisher Scientific, MA, USA) was added to inactivate triple express 
and the cells were pipetted up and down to break any clumps. Cells were then transferred to a 
medium 75 cm2 flask which had 8 mL of media with 10 % FBS (Thermo Fisher Scientific, MA, 
USA) and grown in the incubator until the desired confluency was reached. The same procedure 
was used to sub-culture in to a 175 cm2 flasks, with 5 mL saline or saline-EDTA, 2 mL TrypLE 
express, 3 mL complete media to inactivate trypsin and 20 mL final complete media used.  
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2.5.3 Freezing of cells 
To freeze the cells, 100 % confluent cells in a 175 cm2 flask were washed and detached as described 
above. Following detaching, 10 mL of complete media was added to the cells and centrifuged for 
3 minutes at 5000 g. The supernatant was discarded and the pellet was resuspended with 10 mL of 
freezing media (Appendix 7.3.4). Aliquots of 1 mL were added to cryovials and stored at -80 °C 
overnight then moved to liquid nitrogen for long term storage.  
 
2.5.4 Transfection  
Cells were seeded at 50 % into 60 mm plates or 24 well-plates a day before transfection as 
described in section 2.5.2.   
 
2.5.4.1 PEImax transfection 
An hour before transfection, the medium from the 60 mm plates with 116 cells was replaced with 
5 mL of fresh EMEM media (10 % FBS). The cells were transfected with the Pme I digested 
HDAd plasmid (pHDAd) DNA using the PEImax (Thermo Fischer Scientific, MA, USA) 
transfection method. Two solutions containing 500 µl of OptI-MEM® (Gibco, Life Technologies, 
UK) media were made up. The first solution contained 500 µl of Opti-MEM media and 30 µl of 
PEImax, the second solution contained 500 µl of Opti-MEM and 10 µg in 50 µl Pme I linearized 
pHDAd DNA. The solutions were incubated at room temperature for 10 minutes. The two 
solutions were then mixed together and were incubated at room temperature for 20 minutes. The 
solution mixture was added drop wise to 116 cells on the 60 mm plates with 5 mL of EMEM (10 
% FBS) and incubated overnight at 37 °C in the incubator at 5 % CO2. 
 
2.5.4.2 Lipofectamine® 3000 transfection  
Transfection of Huh7 cells was carried out using Lipofectamine® 3000 transfection kit 
(Invitrogen, Life technologies, UK). A day before transfection, Huh7 cells were seeded to 50 % 
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confluency on a 24 well plate (section 2.5.2) by using DMEM media supplemented with 10 % 
FBS (Thermo Fischer Scientific, MA, USA) and antibiotics. An hour before transfection, the 
medium was removed and 500 µl of fresh antibiotic-free DMEM media with 10 % FBS was added. 
The DNA mix as well as a lipofectamine mix transfection reactions were setup and incubated at 
room temperature for 5 minutes. The DNA mix comprised of the 100 ng of pCH-9/3091 plasmid, 
100 ng of pCI-neo-eGFP plasmid (Table 2.5) and 50 µl of Opti-MEM. For the lipofectamine mix, 
0.2 µl of Lipofectamine®3000 was added to 50 µl of Opti-MEM. The two mixes were mixed 
together and incubated for 15 minutes at room temperature. A total of 100 µl of the transfection 
solution was added to cells drop wise. The cells were incubated for 5 hours in the incubator at 37 
°C. 
 
2.6 Helper virus amplification 
To amplify the previously produced helper virus, about 1.5 × 105 HEK293 cells were seeded in a 
total volume of 15 mL 5 % FBS media in a 150 cm2 plate. The cells were immediately infected 
with Helper virus (HV) at an MOI of 0.1 and incubated at 37 °C. The spent media was replaced 
with fresh media every 48 hours for 10 days, whereby suspended cells were harvested by 
centrifugation and put back in to the plate. After 10 days, the cells were scraped off in to the spent 
media and transferred in to 50 mL Falcon tubes. Then 1.5 mL of 40 % sucrose was added, cells 
were lysed by three freeze-thaw cycles and stored at – 80 °C.  
 
2.6.1 Titration of HV using immunocytochemical staining  
Following HV amplification, infectious units (ifus) were determined by immunocytochemical 
staining using Ultra-Sensitive ABC Peroxidase Mouse IgG staining kit (Thermo Fisher Scientific, 
MA, USA) according to manufacturer’s instructions. Briefly, HEK293 cells were seeded in a 24 
well-plate to 50 % confluency in 10 % media (section 2.5.2). The next day the media was removed 
and cells were washed with 5 % FBS containing media. HV was then diluted (100-10-3) in 50 µl of 
5 % media and added to the cells.  To allow attachment, cells were incubated at 37 0C for 1 hour 
rocking the plate every 10 minutes before 450 µl of 5 % FBS DMEM was added to the wells. The 
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cells were then incubated at 37 °C for 48 hours. The media was removed from the plate, the plate 
was allowed to dry and the cells were fixed with 300 µl of ice cold methanol and incubated at -20 
°C for 10 minutes. The cells were washed 3 × with 1×PBS then blocked with 5 drops of blocking 
buffer and incubated at room temperature for 20 minutes. The cells were washed once with PBS, 
permeabilised by adding 200 µl of permeabilisation buffer and incubated for 5 minutes at room 
temperature. The cells were washed once with PBS, 5 drops of Adenovirus Fiber antibody 
(BIOCOM biotech, Gauteng, South Africa) diluted 1000× in blocking buffer was added and 
incubated at room temperature for an hour. The cells were then washed 3× with PBS, 5 drops of 
biotinylated secondary antibody were added and incubated at room temperature for 30 minutes. 
PBS was used to wash cells (3×), 5 drops of the ABC reagent were added and incubated at room 
temperature for 30 minutes. The cells were washed 3× with PBS, 300 µl of the 1× 3,3'-
Diaminobenzidine (DAB) substrate (Roche Diagnostics, GmbH, Germany) was added to the cells 
and incubated at room temperature until the brown stain can be visualised. The cells were viewed 
and brown stained cells counted under the light microscope. 
 
2.7 HDAds production and amplification 
2.7.1 Production of HDAds 
Hek293 derived 116 cells were seeded at 50 % into 60 mm plates a day before transfection as 
described in section 2.5.3. The media was changed an hour before transfection, where 5 mL of 
spent EMEM was replaced with fresh media. An amount of 10 µg of the pHDAd DNA (pHDAd-
pri-miRNA-31/5 or pHDAd-pri-miRNA-31/589 or pΔ28E4 or pΔ28E4lacZCMV) was digested 
with Pme I restriction enzyme in 50 µl was used to transfect 116 cells using PEImax (section 
2.5.4.1, Thermo Fischer Scientific, MA, USA) to produce HDAd-pri-miRNA-31/5 or HDAd-pri-
miRNA-31/589 or HDAd28E4 or HDAdlacZCMV.  
One day after transfection, HV at an MOI of 5 in 1 mL EMEM supplemented with 5 % FBS was 
added to the cells. To allow attachment, cells were incubated for an hour at 37 °C with rocking 
every 10 minutes. The media was then topped up to 2.5 mL with EMEM media supplemented with 
5% FBS and incubated for 48 hours at 37 °C to allow selective production of HDAds. The cells 
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were examined for complete cytopathic effect (CPE) and scraped off in to the spent media with a 
cell scraper. Sucrose was then added to 4 % and the cells were transferred to 2 mL sterile Eppendorf 
tubes. The cells were subjected to three freeze/thaw cycles in liquid nitrogen and 37 °C water bath. 
Cell lysates were stored at -80 °C.  
2.7.2 Amplification of HDAds 
About 70 % 116 cells confluent 60 mm plates were co-infected with HV at MOI 2 and HDAd in 
the 400 µl of cell lysate from the production step (Section 2.7.1). For adsorption, 600 µl of EMEM 
media supplemented with 5 % FBS was added to the plate and incubated at 37 °C for an hour, 
rocking every 10 minutes. An hour post infection, 1.4 mL of EMEM media supplemented with 5 
% FBS was added and incubated for 48 hours at 37 °C. The cells were examined for complete 
cytopathic effect (CPE) and then scraped off in the spent media with a cell scraper. Sucrose was 
then added to 4 % and the cells were transferred to 2 mL of sterile tubes. The cells were subjected 
to three freeze/thaw cycles in liquid nitrogen and 37 °C water bath. The cell lysates were stored at 
-80 °C. This coinfections and harvesting was repeated until maximum HDAd titres were obtained 
in 60 mm plates. The lowest passage with highest titres was then used to co-infect 70 % confluent 
116 cells in a 150 mm dish with helper virus at a MOI of 2. The co-infected cells were harvested 
after 48 hours and centrifuged at 5000 g for 5 minutes. Supernatant was discarded and the pellet 
was resuspended in 1mL of 100 mM Tris-HCl (pH 8) and used for large scale production. A control 
HDAd vector expressing the lac Z gene (HDAdlacZCMV) was amplified in parallel for easy 
quantification of the number of infectious units.  
 
2.7.3 X-gal staining  
To assess successful production and monitor HDAd amplification, various dilutions (100 -10-5) of 
the HDAdlacZCMV were made in EMEM media supplemented with 5 % FBS up to a volume of 
50 µl. The dilutions were added to 70 % confluent 116 cells in a 24-well plate and incubated for 
at 37 °C for an hour, rocking every 10 minutes.  An hour post infection, 450 µl of EMEM media 
supplemented with 5 % FBS was added and incubated for 48 hours at 37 °C. After the incubation 
period, the media was removed from the plate. The plate was allowed to air-dry at room 
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temperature for 5 minutes, 300 µl of the fixative (1 % formaldehyde and 0.5 % glutaraldehyde) 
was added to the cells and incubated for 10 minutes at room temperature. The cells were washed 
twice with 300 µl of 1 × PBS. The staining solution (4 mM K+ Ferricyanide, 4 mM K+ 
Ferrocyanide, 2 mM MgCl2 and 40 mg/mL of 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside 
(X-gal) in DMSO was added to the cells and incubated for 2-16 hours at 37 °C. The cells were 
observed under a microscope and blue stained cells were counted to determine ifus/mL. 
 
2.7.4 Large scale preparation of HDAds 
Suspension 116 cells were prepared by transferring 20 mL of spent EMEM media supplemented 
with 10 % FBS from eight 100 % confluent 175 cm2 flasks of 116 cells into 3 L spinner flasks. A 
volume of 5 mL of saline was added to 116 cells in 175cm2 flask, incubated for 3 minutes at 37 
°C. The cells were detached by tapping the flask on the side and transferred to 3 L spinner flasks 
containing the spent media. The media was topped up to 1 L with fresh JEMEM media (Section 
2.5.1) and incubated at 37 °C on a magnetic stirrer at 60 rpm. In two days, 0.5 L of fresh JEMEM 
media (Section 2.5.1) was added and continued incubating overnight with stirring. A volume of 1 
L of fresh JEMEM media (Section 2.5.1) was added and incubated overnight with stirring. To 
monitor cell growth and health, every time before adding fresh media, 116 cells were counted by 
transferring 2 mL of cells into a 15 mL Falcon tube and 2 mL of 2 × citric saline was added. The 
cells were vortexed for 10 seconds, incubated for 10 minutes at 37 °C then vortexed again for 10 
seconds. Equal amounts of cells and trypan blue stain were mixed and hemocytometer was used 
to obtain cell counts. About 100 µl of the cell suspension from the 3 L was added to 400 µl of 
JEMEM media (Section 2.5.1) in a 24-well plate and incubated at 37 °C.  
For co-infections, the cells were harvested from the 3 L culture by centrifuging at 750 g for 5 
minutes at room temperature and 0.5 L of spent media was reserved. The cell pellet was 
resuspended in 100 mL spent media and transferred to a 250 mL spinner flask. The cells were 
coinfected by adding HV at MOI 2 and 1 mL of the HDAd lysate from the 150 mm plate 
amplification (Section 2.7.2) and incubated for 2 hours at 37 °C spinning at 60 rpm. The coinfected 
cells were transferred to a 3 L spinner flask, 0.5 L spent media was added and topped up to 2 L 
with JEMEM media (Section 2.5.1). The spinner flasks were incubated spinning at 60 rpm for 48 
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hours at 37 °C. The cells were then harvested by centrifugation at 750 g for 5 minutes at room 
temperature. The cells were resuspended in 15 mL of 100 mM Tris-HCl (pH 8) supplemented with 
glycerol to 10 %, transferred to 50 mL Falcon tube and stored at – 80 °C. 
 
2.7.5 HDAd purification 
For lysis, 2 mL of 5 % sodium deoxycholate was added to the large scale coinfected cells and 
incubated for 30 minutes at room temperature with frequent mixing. MgCl2, RNAse A and DNase 
I were added to 2 mM, 10 µg/mL and 10 µg/mL respectively. The solution was incubated for 1 
hour at 37 °C with constant mixing, followed by centrifugation at maximum speed for 10 minutes. 
The HDAd containing supernatant was removed and the pellet was discarded. Caesium chloride 
(CsCl) step gradients were prepared in SW 55 ultra-clear ultra-centrifuge tubes (two per virus) by 
adding 2 mL of 1.35 g/mL CsCl to each tube and overlaying with 3 mL of 1.25 g/mL CsCl. The 
supernatant was overlaid on top of the two CsCl steps and centrifuged in an ultracentrifuge with 
an SW 40 rotor at 91 349 g for 1 hour. An 18-guage needle and a 3-cc syringe were used to retrieve 
the vector from the tubes. The vector was transferred into one SW 55 ultra-clear tube and topped 
up with 1.35 g/mL CsCl. This was centrifuged overnight at 91 349 g. A 1-cc syringe and 22-guage 
needle was used to retrieve the virus band and it was transferred into a Slide-A-Lyzer dialysis 
cassette pre-soaked with dialysis buffer (10 mM Tris-HCl, pH 8) at 4 °C. This was dialyzed at 4 
°C with slow stirring and three 500 mL changes of dialysis buffer to remove CsCl. A 22-guage 
needle with a 1-cc syringe were used to retrieve the virus from the cassette and glycerol was added 
to 10 %. Aliquots of 50 µl were made and stored at -80 °C.  
 
2.7.6 HDAd quantification and HV contamination determination by 
qPCR 
The quantify CsCl purified HDAd and determine HV contamination, DNA prepared using the 
QIAamp DNA Mini Kit and QIAamp DNA Blood Mini Kit (Qiagen, CA, USA) following the 
blood and body fluid spin protocol according to the manufacturer’s instructions was used for 
qPCR. Briefly, 20 µl of proteinase K was added to 1.5 mL microcentrifuge tube, 50 µl of purified 
39 
 
HDAd was diluted in 150 µl PBS and added to the microcentrifuge tube with proteinase K. A 
volume of 200 µl of lysis buffer AL was added to the sample and mixed by pulse-vortexing for 15 
seconds and incubated at 56 °C for 10 minutes. Absolute ethanol (200 µl) ethanol was added to 
the sample and mixed by pulse-vortexing for 15 seconds. The mixture was added to QIAamp Spin 
Column in a 2 mL collection tube and centrifuged at 6000 g for 1 minute. The QIAamp Spin 
Column was placed in a clean 2 mL collection tube, 500 µl buffer AW1 was added and centrifuged 
at 6000 g for 1 minute. The QIAamp Spin Column was placed in a clean 2 mL collection tube, 500 
µl buffer AW2 was added and centrifuged at 20 000 g for 3 minutes. The QIAamp Spin Column 
was placed in a new 2 mL collection tube and centrifuged at 6000 g for 1 minute. The QIAamp 
Spin Column was placed in a clean 1.5 mL microcentrifuge tube, 50 µl dH2O was added and 
incubated at room temperature for 1 minute, and then centrifuged at 6000 g for 1 minute. To obtain 
the Ad titers, 2 µl of the prepared DNA was used for qPCR (Section 2.3.4) using the HV and 
HDAd primers (Table 2.2) and % HV contamination was calculated. 
2.8 Northern blot hybridization  
2.8.1 RNA extraction 
To determine pri-miRNA expression by recombinant HDAds in vitro, Huh 7 cells were seeded 
and grown to 90 % prior to infection with recombinant HDAds at MOI of 1000. Forty-eight hours 
post infection, the media was discarded and 1 mL of Trizol (Thermo Fisher Scientific, MA, USA) 
was added to the cells. The cells were lysed by pipetting up and down and transferred to 2 mL 
sterile tubes.  The lysates were incubated for 5 minutes at room temperature, 200 µl of chloroform 
was added per mL of Trizol (Thermo Fisher Scientific, MA, USA). The solution was mixed by 
shaking vigorously for 15 seconds and it was incubated for 3 minutes at room temperature. The 
mixture was centrifuged at 20 000 g for 15 minutes at 4 °C. The top aqueous phase was transferred 
to a clean sterile tube and 500 µl of isopropanol was added and mixed. This was incubated at room 
temperature for 1 minute then centrifuged at 20 000 g for 10 minutes at 4 °C. The supernatant was 
discarded and the pellet was washed with 1 mL of 75 % ethanol. The pellet was centrifuged at 
20 000 g for 5 minutes at 4 °C. The pellet was air dried for 5-10 minutes and resuspended in 50 µl 
of RNAse free water. The concentration was measured on the Nano-drop spectrophotometer, 
aliquots of 3 µg were made and stored at -80 °C. 
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2.8.2 Radioactive labelling of decade RNA marker (ladder) 
In a nuclease free tube, 100 ng of the decade RNA marker (1 µl), 6 µl nuclease free water, 1 µl of 
10 × kinase reaction buffer, 1 µl of [γ-32P] ATP and 1 µl of T4 polynucleotide kinase were mixed. 
The solution was incubated for an hour at 37 °C, 8 µl of nuclease free water and 2 µl of cleavage 
reagent were added and incubated for 5 minutes at room temperature. RNA gel loading buffer II 
(20 µl, Thermo Fisher Scientific, MA, USA) was added and aliquots of 5 µl were made and stored 
at – 80 °C. 
 
2.8.3 Radioactive labelling and purification of probes 
A volume of 2 µl of 10 µM probe was mixed in a tube with 2 µl of polynucleotide kinase (PNK) 
buffer A, 1 µl PNK and 1 µl [γ-32P] ATP. The volume was made up to 20 µl with water and the 
solution was incubated for 45 minutes at 37 °C. The sephadex column was prepared by inserting 
1 cm of fish tank wool at the bottom of a 1 mL syringe. Sephadex (0.9 mL, Appendix 7.4.2) was 
added to the syringe and centrifuged at 5000 g for 2 minute in a 15 mL Falcon tube. The labelled 
probe was topped up with 30 µl of water and added to the column. The column was centrifuged at 
5000 g for 2 minutes and the probe collected in a 15 mL Falcon tube.   
 
2.8.4 Polyacrylamide gel electrophoresis 
A 15 % polyacrylamide gel was set the day before running the gel. This was prepared by adding 
0.45 g of N-N-methylenebisacrylamide, 8.55 g of acrylamide and 28.8 g of urea to 6 mL of 10 × 
TBE buffer (pH8, Appendix 6.4.3). About 20 mL of Sabax water was added and the solution was 
stirred in warm water until it completely dissolved. It was topped up to 60 mL with highly pure 
(Sabax) water, 300 µl of 1 % ammonium persulfate and 30 µL of N,N,N,N-Tetramethylethyl 
enediaminne (TEMED) were added. The gel was poured with 1 mL pipette tip and allowed to set. 
Wet paper towel was used to cover the top of the gel apparatus and it was covered with cling film 
and left overnight. The next day, the gel was transferred to a running tank and filled with 1 × TBE 
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(Appendix 7.4.3) buffer and the gel was pre-run for 30 minutes at 150 V before loading. An equal 
volume of RNA loading dye was added to 30 µg of RNA, these were denatured at 80 °C, whereas 
the ladder was denatured at 95 °C for 5 minutes. A syringe with a needle on was used to flush each 
well with running buffer before loading. The samples were loaded with the Hemilton syringe at 
the bottom of each well and the gel was run at 200 V. The gel was stained with 50 µl of ethidium 
bromide in 500 mL running buffer for 5 minutes. The gel was put on a plastic and viewed on the 
gel doc to confirm the quality of RNA.  
 
2.8.5 Blotting 
The wells on the gel were trimmed with a scalpel. Six pieces of the thick filter paper and a nylon 
membrane of the same size as the gel were cut. These were soaked in running buffer and a 
sandwich was made in a semi-dry blotter by putting three filter papers, the nylon membrane, the 
gel and three filter papers. Excess liquid was pressed out by rolling a 10 mL plastic pipette. The 
RNA was transferred to the nylon membrane by running at 0.77 A for 45 minute using a Semi-
Dry Electroblotting Unit (Sigma-Aldrich, MO, USA).  
 
2.8.6 UV crosslinking and hybridization 
The nylon membrane was removed from the sandwich, put on a filter paper and cross linked for 2 
minute using an Ultra-Violet cross linker (UVP Inc., CA, USA).  Hybridization buffer (10 mL) 
was heated to 42 °C in a hybridizing bottle. The membrane was placed in the bottle and pre-
hybridized for 20 minutes. The labelled probe was denatured at 95 °C for 5 minutes, added to the 
bottle and hybridized overnight rotating at 42 °C. 
 
2.8.7 Stringency washes and exposure 
The hybridization buffer was removed; the membrane was washed with 50 mL of 5 × SSC and 0.1 
% SDS at room temperature for 20 minutes. The membrane was then washed twice with 50 mL of 
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1 × SSC and 0.1 % SDS at 42 °C for 15 minutes. The membrane was placed in a plastic and put 
together with imaging plate in a cassette and stored at room temperature in the drawer for one 
week exposure. The imaging was performed using the FUJIFILM FLA-7000 phosphor-imager 
(Vacutec, Gauteng, SA). 
 
 
2.9 Assessment of HBV replication inhibition in cultured cells 
by Enzyme Linked Immunosorbent Assay (ELISA) 
Huh7 cells were transfected with pCH-9/3091 as well as with eGFP plasmids using 
Lipofectamine® 3000 (section 2.5.4.2).    Five hours after transfection, HDAds at various MOIs 
(500, 1000, 2000 and 4000) in 50 µl of 5 % media was added to the cells.  To allow attachment, 
cells were incubated at 37 0C for 1 hour rocking the plate every 10 minutes before 450 µl of 5 % 
FBS DMEM was added. The cells were then incubated at 37 °C. Forty eight hours post infection, 
knockdown of HBV replication was assessed by measuring HBV surface antigen (HBsAg) which 
is a marker of HBV gene expression secreted into culture supernatant by ELISA using 
MONALISATM HBsAg Ultra Kit (Bio-Rad, CA, USA) following the manufacturer’s instructions. 
Briefly, 100 µl of unknown samples, positive and negative controls were added to the wells of the 
microplate. A volume of 50 µl of the conjugate solution was added to each well. The plate was 
covered with adhesive film and incubated for 1 hour 30 minutes at 37 °C. The plate was washed 
using the automatic microplate washer system and the strips were dried. The development solution 
was prepared and 100 µl was added to each well. The plate was incubated in the dark for 30 
minutes, 100 µl of the stopping solution was added and incubated for 4 minutes at room 
temperature. The plate was placed inside the microplate reader (Bio-Rad Laboratories, CA, USA) 
and the optical density was read at 490nm. 
2.10 In vivo methods 
In this study, HBV transgenic mice which express HBV particles were used according to the 
protocols approved by the University of the Witwatersrand Animal Ethics Committee. All the 
sampling, handling and injections of animals were done in the Wits central animal service (CAS), 
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therefore no transportation of animals from CAS was required. Mice which were used were 4-8 
weeks old and they were bled by retro-orbital puncture 3 days before injection and used as baseline. 
The mice (4 - 6 mice/group) were injected with 1 × 1010 HDAd particles via the tail vein; blood 
was collected via retro-orbital puncture following injections. Weights of the mice were monitored 
throughout the experiments. The serum samples were used to assess HBV replication inhibition, 
immune stimulation and toxicity of the HDAds by measuring levels of HBsAg, inflammatory 
cytokines and alanine liver enzyme levels respectively. For liver transduction and pri-miRNA 
expression assessment, following injections the mice were sacrificed by carbon dioxide exposure, 
livers harvested and mice disposed as recommended by CAS staff. 
 
2.10.1 Assessment of liver transduction and transgene expression by 
recombinant HDAds in vivo 
As mentioned previously, HDAds expressing pri-miRNA expression cassettes from a liver-
specific promoter were used in this study. To assess if these HDAd were able to efficiently deliver 
these pri-miRNA expression cassettes to the liver, DNA was extracted from the livers of mice 
injected with 1 × 1010 HDAd particles after one week. DNA was prepared from the livers using 
QIAamp DNA Mini Kit (Qiagen, CA, USA) following the tissue protocol according to the 
manufacturer’s instructions. Briefly, Proteinase K (20 µl) and 200 µl of buffer ATL were added in 
to a 2 mL micro-centrifuge tube containing 200 µl of the liver homogenate. This was mixed by 
vortexing, and incubated at 56 °C for 3 hours. A volume of 200 µl of the lysate was then used to 
isolate viral DNA according the blood and body fluid spin protocol as outlined in section 2.7.6. 
The concentration of the DNA was measured on the Nano-drop spectrophotometer and 100 ng was 
used for qPCR (Section 2.3.3) using HDAd primers (Table 2.2). 
For pri-miRNA expression and processing in vivo, livers were harvested in TRIzol (Thermo Fisher 
Scientific, MA, USA) from mice at one week post infection with 1 × 1010 HDAd particles. Livers 
were homogenised, RNA isolated and 30 µg used for Northern blot analysis as described in section 
2.8. 
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2.10.2 Determination of HBV replication inhibition in mice 
HBsAg was measured by ELISA in serum samples collected before HDAd injection, at one and 
two weeks post infection. Serum samples diluted 50 × in 100 µl of saline were used for ELISA 
using the Monolisa™ HBsAg Ultra Kit (Bio-Rad Laboratories, CA, USA) as per manufacturer’s 
instructions and summerised in section 2.9.  
 
2.10.3 Assessment of inflammatory response and toxicity of recombinant 
HDAds 
For inflammatory response assessments, blood samples were collected and serum harvested at 0, 
6 and 24 hours post injection of mice with HDAd. Cytometric bead array (CBA) was performed 
by using the mouse inflammation kit BDTM (The Scientific Group, South Africa). Briefly, 
Standards were reconstituted in 2 mL of assay diluent, incubated for 15 minutes at room 
temperature and mixed by pipetting. Serial dilutions were then performed in the assay diluent. 
Cytokine Capture beads were mixed by adding 10 µl of each capture bead for each assay tube to 
be analysed. The standards or serum samples were transferred to tubes containing the capture beads 
and 50 µl of PE detection reagent was added. Assay tubes were incubated at room temperature in 
the dark for 2 hours, 1 mL of wash buffer was added and centrifuged at 5000 g for 5 minutes. Each 
bead pellet was resuspended with 300 µl of wash buffer. Samples were analysed in the 
LSRFortessaTM flow cytometry instrument and FCAP ArrayTM software (BD Bioscience, CA, 
USA) was used to quantify serum levels of inflammatory markers: IL-6, IL-10, MCP-1, IFN-γ, 
TNF and IL-12p70. For hepatotoxicity determination of the recombinant HDAds, serum samples 
were collected at 72 hours, one week and two weeks post injection with HDAds and sent to 
National Health Laboratory Service chemistry laboratory for alanine aminotransferase (ALT) 
activity assay on an automated photomeric analyser (Roche Diagnostics, Rotkreuz, Switzerland). 
 
2.11 Data analysis 
For statistical analysis, data were expressed as the mean ± standard error of the mean (SEM). 
Statistical difference was determined by using Student’s 2-tailed t-test and was considered 
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significant when P ≤ 0.05. Calculations were done with GraphPad Prism software (GraphPad 
Software Inc., CA, USA). 
 
CHAPTER 3 
3. RESULTS 
3.1 Successful cloning of anti-HBV pri-miRNA expression cassettes 
into p∆28E4 backbone 
Previously, monomeric and trimeric anti-HBV pri-miRNAs targeting HBx region of HBV were 
designed (Ely et al., 2009). These were delivered using HDAd co-expressing β-galactosidase as a 
reporter for easy viral quantification and assessment of transduction efficiency. However, the 
expression of the reporter gene has been shown to induce an immune response, resulting in quicker 
vector clearance and decreased HDAd efficacy (Crowther et al., 2014, Mowa et al., 2014). To 
overcome this, HDAd plasmids devoid of the lac Z gene and expressing pri-miRNA sequences 
from the liver-specific mouse transthyretin receptor (MTTR) promoter were constructed in this 
study (Figure 3.1).  
 
Figure 3.1 Generation of HDAd plasmid constructs with the desired anti-HBV sequences. A) 
Part of HDAd plasmid with the anti-HBV sequence expressed from a MTTR promoter and a lac 
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Z reporter gene. B) Part of HDAd plasmid deficient of lac Z and containing pri-miRNA sequence 
expressed from MTTR promoter, the dotted line represents the deleted region.   
To construct HDAd plasmids (pHDAds) containing pri-miRNA sequences under the control of 
MTTR promoter, anti-HBV pri-miRNA cassettes were cut out from the previously constructed 
pTZ plasmids [pTZMTTR-pri-mi-R-31/5 and pTZMTTR-pri-mi-R-31/5-8-9, (Mowa et al., 
2014)]. These were then ligated in the AscI site of lac Z deficient p∆28E4 plasmid (Donated by 
Phillip Ng, Baylor College of Education, USA) to form pHDAd-pri-miRNA-31/5 and pHDAd-
pri-miRNA-31/589.  AscI was used to screen for positive clones (Data not shown). Successful 
cloning of the anti-HBV expression cassettes into p∆28E4 was confirmed by restriction enzyme 
digestion of one positive clone with AscI, NdeI and PmeI restriction enzymes (RE) and Table 3.1 
shows the expected sizes as determined using vector NTI (Thermo Fisher Scientific, MA, USA). 
Figure 3.2 A shows the digestion of constructed pHDAd expressing pri-miRNA-31/5 (pHDAd-
pri-miRNA-31/5).  
As expected, pHDAd-pri-miRNA-31/5 digested with AscI, NdeI and PmeI resulted in 31 033 bp 
& 1794 bp or 21 524 bp, 5912 bp & 5391 bp or 29 878 bp & 2949 bp bands respectively. Digestion 
with NdeI of Figure 3.2 A only has 2 bands instead of 3, which is likely to be a result of co-
migration of the DNA fragments of 5912 bp and 5391 bp. Figure 3.2 B shows the constructed 
pHDAd expressing pri-miRNA-31/589 (pHDAd-pri-miRNA-31/589). Digestion of pHDAd-pri-
miRNA-31/589 with AscI, NdeI and PmeI gave rise to 31 043 bp & 2117 bp or 21 524 bp, 6245 
bp & 5391 bp or 30 211 bp & 2949 bp bands respectively. Again, digestion with NdeI of Figure 
3.2 B only has 2 bands instead of 3, this may be due to the fact the last two bands, 6254 bp and 
5391 bp are close to each other and may not have separated from each other. PmeI digestion 
separated the bacteria from the adenoviral genome, this was important as the PmeI linearized 
plasmids were later used for HDAd production. As compared to the uncut controls that resulted in 
one slow migrating band and considering the expected bands for the empty plasmid  shown on 
Table 3.1, the fragment sizes obtained following RE digest of the constructs with the various 
enzymes match the expected sizes obtained from vector NTI software (Table 3.1). As a result of 
their greater length (~ 24 - 35 kb), adenoviral genome-carrying plasmids are very difficult to 
manipulate for cloning purposes. However, these data show that pri-miRNA expression cassettes 
were successfully cloned into the p∆28E4 plasmid, which is 32 827 bp in size.    
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Table 3.1: Expected fragment sizes for the constructs following restriction enzyme 
digestion 
pHDAd construct Restriction enzyme Fragment size (bp) 
1. pHDA-pri-miRNA-
31/5 
 
 
AscI 31 033 bp & 1794 bp 
NdeI 21 524 bp, 5912 bp & 5391 bp 
PmeI 29 878 bp & 2949 bp 
2. pHDAd-pri-miRNA-
31/589 
AscI 31 043 bp & 2117 bp 
NdeI 21 524 bp, 6245 bp & 5391 bp 
PmeI 30 211 bp & 2949 bp 
3. p∆28E4 AscI 31 027 bp 
NdeI 21 524bp, 5391 bp & 4112 bp 
PmeI 28 078 bp & 2949 bp 
Red indicates the bands that migrate together on the gel 
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Figure 3.2 Construction of HDAds expressing anti-HBV pri-miRNA expression cassettes 
from MTTR promoter. Anti-HBV pri-miRNA31/5 (A) and pri-miRNA31/5-8-9 (B) sequences 
expressed from MTTR promoter were sub cloned into the HDAd (p∆28E4) backbone at the AscI 
restriction enzyme (RE) site. Positive clones were verified by AscI, NdeI and PmeI RE digestion. 
A) Shows the constructed pHDAd expressing pri-miRNA-31/5 (p∆MTTR-pri-miRNA-31/5). 
Lane 1 and 6 show the O’gene ladder that was used with sizes from 100 bp to 10 000 bp, lane 2 
shows uncut p∆MTTR-pri-miRNA-31/5, lane 3 shows p∆MTTR-pri-miRNA-31/5 digested with 
AscI RE, lane 4 shows p∆MTTR-pri-miRNA-31/5 digested with NdeI RE and lane 5 shows 
p∆MTTR-pri-miRNA-31/5 digested with PmeI RE. B) Shows the constructed pHDAd expressing 
pri-miRNA-31/589 (p∆MTTR-pri-miRNA-31/589). Lane 1 and 6 show the O’gene ladder that was 
used with sizes from 100 bp to 10 000 bp, lane 2 shows p∆MTTR-pri-miRNA-31/589 uncut, lane 
3 shows p∆MTTR-pri-miRNA-31/589 digested with AscI RE, lane 4 shows p∆MTTR-pri-
miRNA-31/589 digested with NdeI RE and lane 5 shows p∆MTTR-pri-miRNA-31/589 digested 
with PmeI RE. 
 
3.2 HDAd production 
Since all the viral coding sequences are removed, HDAds require a helper virus (HV) for their 
propagation (Palmer and Ng, 2005). Despite the fact that HDAds are devoid of all their viral coding 
sequences, immune stimulation by the capsid proteins still remains a daunting obstacle that makes 
these vectors unsafe in clinical application. Several studies have shown that PEGylation of Ads 
reduce immune stimulation (Kreppel and Kochanek, 2008). Unlike using a non-residue specific 
amine reactive PEG, introduction of cysteine residues on the adenoviral capsid enable residue 
specific PEGylation using thiol reactive PEG, and this has been shown to improve transduction 
efficiency and diminish Ad specific immune stimulation (Prill et al., 2011). This is achieved by 
using a HV expressing capsid protein with the cysteine modification. Hence in this study, a HV 
with (AdNG163cys) or without (AdNG163) cysteine modification was used. 
    
3.2.1 Amplification of AdNG163cys and AdNG163 helper-viruses  
49 
 
To obtain enough HV for production of HDAds, previously produced AdNG163cys and AdNG163 
HVs were propagated in Hek293T cells. To determine successful amplification, the infectious 
units (ifus) of the HV were quantified by immunocytochemical staining of infected Hek293T cells. 
Interestingly, in comparison with AdNG163 (Figure 3.3 B), imaging of stained cells consistently 
showed brown cells that were clumped together when infected with AdNG163cys (Figure 3.3 C) 
making it difficult to precisely count infected cells (Figure 3.3). Enumeration of ifus for AdNG163 
showed that 3.85× 108 ifus/mL were obtained in a total volume of 20 mL, which was enough for 
HDAd production. As a result of clumping of AdNG163cys infected cells, qPCR was used to 
determine total viral particles, which showed that 3.69 × 109 vps/mL was obtained in a total volume 
of 20 mL. These were comparable with 4.78 × 109 vps/mL obtained with AdNG163.   
 
 
Figure 3.3: Amplification of AdNG163cys and AdNG163 HVs.  AdNG163cys and AdNG163 
HVs were produced and amplified in Hek293T cells. Immunostaining was done to quantify HV 
infectious units. The arrows in the images show the brown cells which were observed following 
staining. 
 
3.2.2 Cysteine modification on the AdNG163cys helper-virus diminish its role 
in HDAd propagation  
Because of the difficulty to determine AdNG163cys ifus, total vps were used to determine the HV 
quantities required for different MOIs tested for production of cysteine modified HDAd 
(HDAdcys) or unmodified HDAd. The MOIs that were tested for HDAd production were MOI 5, 
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10, 20, 50, and 100. HDAd carrying lac Z (pΔ28E4CMVlacZ) gene was produced in parallel for 
convenient quantification of ifus produced by X-gal staining. For HDAd production, 116 cells 
transfected with the pHDAds were infected with AdNG163cys or AdNG163 at various MOIs. 
Cells were then harvested at 48 hours post infection and lysed. X-gal staining of infected cells 
showed that AdNG163 resulted in efficient HDAd production at an MOI of 5 with 1.11×105 ifu/mL 
obtained in a total volume of 2.5 mL. In contrast, HDAdcys could only be produced at 
AdNG163cys MOI of 20. Interestingly, HDAdcys showed similar characteristics with 
AdNG163cys after X-gal staining of infected cells. Clumped blue cells were observed and again, 
making it difficult to determine the produced ifus (Figure 3.4). The observed clumps of blue cells 
further suggest that cys modification result in viral aggregation before or during infection. An 
attempt to amplify HDAdcys at different MOIs of AdNG163cys was unsuccessful (Data not 
shown).  
 
 
 
Figure 3.4: X-gal staining of HDAds produced with AdNG163cys or AdNG163 HVs. 
AdNG163cys and AdNG163 were used for the production of HDAds, A shows uninfected cells, 
B shows cells infected with AdNG163 whereas C shows cells infected with AdNG163cys 
respectively. The arrows show the blue cells that were observed following staining.  
 
 
3.2.3 Effect of cysteine modification on the adenoviral infection efficiency. 
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Signs of viral aggregation and failure to serve as an efficient HV for production and amplification 
of HDAds by AdNG163cys may be as a result of capsid structural changes that affect its infection 
efficiency. Adenoviruses induce morphological changes in the cultured cells upon infection and 
viral gene expression. This is mainly characterized by rounding of infected cells called cytopathic 
effect (CPE). This was taken advantage of in order to asses if the cysteine modification of the 
AdNG163Cys affected the infection efficiency as compared to AdNG163.  
To achieve this, cells were infected with AdNG163 or AdNG163cys at an MOI of 2 and CPE 
assessed by light microscopy after 48 hours. AdNG163 resulted in about 100 % CPE as compared 
to AdNG163cys, which resulted in no or little CPE (Figure 3.5). Hence, suggesting an attenuated 
transduction and the resultant adenoviral gene expression in cells treated with AdNG163cys. 
 
 
Figure 3.5: Cytophatic effect (CPE) of 116 cells infected with AdNG163 and AdNG163cys. 
116 cells were infected with either AdNG163 or AdNG163cys HVs. The arrows indicate CPE 
which indicated by rounded up cells. 
 
3.3 AdNG163cys has an altered particle structure 
The clumping of infected cells suggested that the HV used was aggregating and this might indicate 
changes in capsid structure.  To confirm the structural integrity of the cysteine modified HV, 
transmission electron microscopy (TEM) was performed. As compared to the HDAd control 
hexagon structure, the AdNG163cys particles showed obvious differences with no hexagon shape 
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observed, whereby the particles looked more roundish or collapsed (Figure 3.6). These results 
confirm that modification of the capsids affected the particle structure of the HV.  
 
Figure 3.6: Transmission electron microscopy (TEM) of AdNG163cys and HDAd produced 
from AdNG163 HV. A shows AdNG163cys that was produced whereas B shows the HDAd 
produced by using AdNG163 HV. The arrows are showing the adenoviral particles. 
 
3.4 Successful amplification of HDAds with AdNG163 helper-virus 
As a result of AdNG163cys inability to serve as an efficient helper for HDAd production and 
amplification, lac Z deficient HDAds produced with AdNG163 HV at an MOI of 5 were then 
amplified in parallel with lac Z containing HDAd and characterised. Produced HDAds (P0) were 
amplified by passaging in 116 cells with AdNG163 at MOI 2 until optimal titre were obtained. X-
gal staining of the HDAdlacZCMV control (Figure 3. 7) showed that ifus/mL obtained were: P1 
(4.42 × 105 ifu/mL), P2 (1.86 × 106 ifu/mL), P3 (4.3 × 107 ifu/mL), P4 (3.79 × 109 ifu/mL) and P5 
(1.19 × 109 ifu/mL). As expected, there was an amplification with every passage until ~ 1× 109 
ifu/mL were reached. Optimal titres were reached at P5 for a 60 mm plate (Table 3.2). Therefore, 
the lowest passage with higher titre (P4) was amplified in 150 mm plates (P5b) at MOI 2. The cells 
were lysed and X-gal stain was performed. The ifus/mL were calculated to be 3.3 × 109 ifu/mL 
(Table 3.2) for P5b, which was enough for large scale infections.  
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Figure 3.7: Representative images of HDAds amplification with AdNG163. Amplification 
(P1-P5b) of the HDAds was performed by coinfecting 116 cells with HDAd from previous passage 
and HV at MOI 2. A: uninfected, B-F: Passage 1 to 5 in 60 mm plate, G: Passage 5b amplified 
from P4 in a 150 mm plate. 
 
Table 3.2: Ifus/mL for HDAd constructs at various passages 
 
Passage 
number (P) 
Infectious units 
(ifu/mL) 
Fold 
amplification  
P0 1.11 × 105  
P1 4.42 × 105 3.89 
P2 1.86 × 106 4.21 
P3 4.3 × 107 23.12 
P4 3.79 × 109 88.14 
P5 1.19 × 109 0.31 
P5b 3.3 × 109 2.77 
 
 
 
 
3.5 Large scale production and purification of HDAds 
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To allow in vitro and in vivo characterization, HDAds from P5b were amplified in large scale and 
purified by CsCl gradient. After centrifugation of HDAds in the discontinuous CsCl gradient, as 
expected, one viral band was observed at the bottom of the tube (Figure 3.8A). This was harvested 
and put through a continuous CsCl gradient centrifugation overnight and one band at the top of the 
tube was observed (Figure 3.8B). This represents a pure HDAd virions and it was harvested and 
dialysed overnight to remove Cscl. The total viral particles for the various HDAds and HV 
contamination were determined by q-PCR. HDAdΔ28E4, HDAd-pri-miRNA-31/5 and HDAd-pri-
miRNA-31/589 total viral particles obtained were 2.628 × 1013 vps, 9.63 × 1012 vps and 2.328 × 
1013 vps respectively (Table 3.3). Because of the low amount of HV used during amplification 
and the fact that HV genome becomes unpackageable in Cre expressing cells, HV band could not 
be seen with a naked eye on the gradient, hence this can be harvested and result in HDAd 
contamination with HV. HDAdΔ28E4 was contaminated by 2 % of HV; HDAd-pri-miRNA-31/5 
had HV contamination of 3 % whereas HDAd-pri-miRNA-31/589 had HV contamination of 1.7 
%. This HV contamination was negligible and was not a concern for this study. Hence, enough 
HDAds for in vitro and in vivo studies were   successfully produced and purified.  
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Figure 3.8: A representative CsCl gradient images from large-scale HDAd production and 
purification. Cells coinfected with HDAds and, AdNG163 HV at MOI 2 were harvested by 
centrifugation and purified by CsCl gradient centrifugation. A)  Discontinuous CsCl gradient after 
one hour of centrifugation. B) Continuous CsCl gradient after overnight centrifugation. Arrows 
indicate bands representing the HDAd.  
 
Table 3.3: Purified HDAds, their titres and HV contamination 
 
HDAd  Titres (vps/µl) Total vps  HV contamination 
(%) 
HDAdΔ28E4 8.76 × 109 2.628 × 1013 2 
HDAd-pri-miRNA-
31/5 
3.21 × 109 9.63 × 1012 3 
HDAd-pri-miRNA-
31/589 
7.76 × 109 2.328 × 1013 1.7 
 
56 
 
 
3.6 Anti-HBV pri-miRNA expression and processing in cultured 
cells 
Upon introduction of artificial pri-miRNA expressing cassettes in a host cell, they are expected to 
enter the host RNAi pathway where they will be expressed by the RNA polymerase II, processed 
by Drosha and Dicer to produce pre-miRNA and mature miRNA duplexes of about 20 nucleotides 
(nt) respectively. In this study, in vitro anti-HBV pri-miRNA-31/5 and pri-miRNA-31/589 
expression from HDAds was assessed by Northern blot using the probes complementary to the 
expected guides.  
 As expected, cells infected with HDAd-pri-miRNA 31/5 showed the presence of a single band of 
~21 nt when the blot was probed with guide 5 probe only but not guide 8 and 9 probes. HDAD-
pri-miRNA 31/589 is expected to produce three different guides. However, only guide 5 could be 
detected from the RNA isolated from Huh 7 cells infected with HDAD-pri-miRNA 31/589. This 
could be as a result of differential efficiencies at which the three guides are cleaved from the pre-
miRNA, with guide 5 being produced more abundantly than 8 and 9.  
As expected, RNA from uninfected cells or cells infected with control empty vector resulted in no 
band observed. Supporting the above observations, RNA isolated from Huh 7 infected with HDAd 
co-expressing β-galactosidase and pri-miRNA 31/589 from an MTTR promoter  (Mowa et al., 
2014) resulted in the detection of both guide 5 and guide 8 at different levels, but not guide 9. 
Guide 5 probe also detected a higher molecular weight RNA species, which can be from partial 
processing of precursor-miRNAs (Figure 3.9).   
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Figure 3.9: Expression and processing of anti-HBV pri-miRNA sequences from HDAds. 
RNA was extracted from liver-derived Huh7 cells infected with purified HDAds at MOI 1000. 
The RNA was used for Northern blot hybridization using 32P radioactively labelled probes 
complementary to the expected guide strands. A decade RNA ladder was used to determine the 
sizes of RNA. A shows the decade RNA marker that was used with sizes ranging from 10 – 150 
nucleotides (nt). B, C and D represent membranes that were probed with guide 5, 8, 9 probes 
respectively. 18s and 23s rRNAs from ethidium bromide stained gel were used as a loading control. 
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3.7 Recombinant anti-HBV HDAds significantly inhibit HBV 
replication in cultured cells 
Once the therapeutic pri-miRNAs are expressed and processed to mature miRNA duplexes, they 
are expected to be recognized by host RISC complex where the guide is selected to bind to the 
HBV RNA and effect HBV replication inhibition.  
To assess if lac Z deficient HDAds expressing anti-HBV pri-miRNA sequences can knock down 
HBV replication in vitro, levels of secreted HBsAg (marker of HBV replication) were determined 
by ELISA using culture supernatants from Huh7 transfected with HBV sequence carrying plasmid 
pCH9/3091 and infected with HDAds at MOI 500, 1000, 2000 and 4000.  
A significant reduction in HBsAg expression was observed in cells infected with HDAd-pri-
miRNA-31/5 at MOIs 500, 1000 and 2000 relative to HDAdΔ28E4.  Infection of Huh 7 cells with 
HDAd-pri-miRNA-31/589 resulted in significant and more pronounced HBV gene silencing at 
MOI 1000 and 2000. Surprisingly MOI 500 did not result in HBV replication inhibition for HDAd-
pri-miRNA-31/589. This HBV replication inhibition was dose dependent; however increase of 
MOI to 2000 or 4000 did not increase anti-HBV effects for both HDAd-pri-miRNA-31/5 and 
HDAd-pri-miRNA-31/589. This could be as result of high HDAd particles that may affect the 
health of the cells. ELISA performed after 72 hours post infection, resulted in similar results 
(Figure 3.10).  
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Figure 3.10: Inhibition of HBsAg expression in vitro. Liver-derived Huh7 cells were transfected 
with pCH-9/3091 and infected with anti-HBV HDAds at MOI 500, 1000, 2000 and 4000. ELISA 
was performed 48 and 72 hours post infection to measure the levels of HBsAg. A) and B) show 
HBV gene silencing by HDAd-pri-miRNA-31/5 and HDAd-pri-miRNA-31/589 48 hours post 
infection, whereas C) and D) show HBV gene silencing by HDAd-pri-miRNA-31/5 and HDAd-
pri-miRNA-31/589 72 hours post infection.  HDAdΔ28E4 was used as a negative control and used 
to normalize the data. The graphs were plotted using the normalised mean and normalised standard 
error of the mean (SEM).  The statistical significance was calculated by using a non-paired 
Student’s t-test. P values less than 0.05 (*), 0.01 (**) or 0.0001 (***) were considered statistically 
significant, whereas ns indicates non-significant. 
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3.8 Expression of anti-HBV pri-miRNAs and inhibition of HBV 
replication by HDAds in mice 
 Long-term in vivo transgene expression with reduced immune response stimulation (Suzuki et al., 
2010) makes HDAds more appropriate vectors for liver-directed gene therapy. To assess HBV 
gene silencing in vivo, HDAd-pri-miRNA-31/589, which showed the most effective HBV gene 
silencing in vitro and HDAdΔ28E4 as a negative control were used to infect HBV transgenic mice. 
Mice were grouped into groups of 4-6 mice and injected with 1 × 1010 HDAd particles via the tail 
vein. Blood samples were collected by retro-orbital puncture at day 0, 1 week and 2 weeks post 
infection. ELISA was then performed to determine serum HBsAg levels. Surprisingly, the levels 
of HBsAg in mice infected with HDAd-pri-miRNA-31/589 were not statistically different to those 
in HDAdΔ28E4 infected mice at both one and two weeks post infection (Figure 3.11).  
To assess if lack of HBV knockdown was as a result of lack of pri-miRNA expression or 
processing, mice were infected with HDAd-pri-miRNA-31/589 or HDAdΔ28E4 and RNA was 
extracted from the livers after 1 week post infection. Northern blotting was then performed with 
30 µg RNA of hepatic RNA using 32P radioactively labelled probes complementary to the expected 
guide 5, 8 and 9. Unlike in the RNA isolated from Huh 7 cells infected with HDAdlacZ pri-miR 
589, there was no 21 nt guide 5, 8 or 9 detected from RNA isolated from HDAd-pri-miRNA-
31/589 infected livers (Figure 3.12). This supports the lack of HBV silencing data by ELISA 
shown on Figure 3.11.  
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Figure 3.11: Lack of inhibition of HBsAg expression in HBV transgenic mice. HBV transgenic 
mice were grouped and injected via the tail vein with 1 × 010 HDAd particles. Blood was collected 
and the serum was used to analyze HBV replication inhibition by HBsAg ELISA. The graphs were 
plotted using the normalized mean, error bars represent normalized standard error of the mean 
(SEM).  The statistical significance was calculated by using a non-paired Student’s t-test, where 
ns means non-significant. 
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Figure 3.12: Expression and processing of anti-HBV pri-miRNA sequences from HDAds in 
vivo. HBV transgenic mice were grouped and injected via the tail vein with 1 × 1010 HDAd 
particles. RNA was extracted from mice livers for Northern blot hybridization using 32P 
radioactively labelled probes complementary to the expected guide strands. A decade RNA 
ladder was used to determine the sizes of RNA. A shows the decade RNA marker that was used 
with sizes ranging from 10 – 150 nucleotides (nt). B, C and D represent membranes that were 
probed with guide 5, 8, 9 probes respectively. 18S and 23S rRNAs from ethidium bromide 
stained gel were used as a loading control. 
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There are several possibilities that could result in insufficient pri-miRNA expression and silencing 
of HBV replication by HDAds: 1) Because total viral particle quantification was used to determine 
the viral particles required to observe gene knockdown, this observation might have been as a 
result of insufficient infectious units used to transduce the liver. 2) HDAds might be inducing a 
strong inflammatory response that may result in clearance of the vector infected cells and toxicity. 
3) As a result of time constrains, transgenic mice with moderate HBsAg levels (OD 0.3 to 0.6) 
could not be obtained when required, hence mice with higher HBsAg titres (OD 08 to 0.9) were 
used, and in our hands, these do not precisely demonstrate the efficacy of pri-miRNAs used.   
3.9 Assessment of HDAds liver transduction, induction of an 
inflammatory response and liver toxicity  
To determine whether HDAds transduced the liver efficiently, DNA was isolated from liver tissue 
harvested from mice at one week postinfection with 1 × 1010 vps HDAds and used for qPCR using 
HDAd specific primers. HDAd viral particles of about 4.00 ×105 VPEs/µg DNA were detected in 
the livers (Figure 3.13). These levels are comparable to levels previously observed and they should 
result in a significant HBV gene silencing (Mowa et al., 2014). 
 
 
Figure 3.13: HDAd vector copies per µg of hepatocyte DNA. Mice were injected via the tail 
vein with saline and a single dose of 1 x 1010 HDAd particles. Mouse livers were extracted after 1 
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week and DNA was isolated and subjected to q-PCR to determine HDAd genome copies in the 
hepatocytes.  
 
To determine if HDAd pri-miRNA 31/589 used  induces a strong inflammation of the liver, a 
cytometric bead array was used to measure levels of circulating inflammatory markers IL-6, IL-
10, IL-12p70, MCP-1, IFN-γ and TNF at 0 hours,  6 hours and 24 hours post injection with saline 
or HDAdΔ28E4 or HDAd-pri-miRNA-31/589 or Poly IC as a positive control. As compared to 
saline, there was no significant induction of inflammatory marker expression at 0, 6 and 24 hours 
post infection with either of the HDAds. As expected, poly IC significantly induced expression of 
TNF, MCP-1, IL-10 and IL-6 6 hours post infection but didn’t induce expression of IL-12p70 and 
IFN-γ. Surprisingly poly IC group had elevated levels of IL-12p70, which must have been from a 
condition unrelated to the experiment. Even more puzzling, this cytokine was back to normal at 6 
hours after injection (Figure 3.14a). 
To determine whether HDAd pri-miRNA 31/589 induces any liver toxicity, alanine 
aminotransferase (ALT) levels  in serum samples collected at 0 hours, 72 hours, 1 week and 2 
weeks post injections was determined by ALT activity assay. Levels of ALT in all the groups 
remained below the acceptable cut off of 100 U/L at all the time points (Figure 3.15); therefore 
the anti-HBV HDAds used in this study did not induce any obvious liver damage. 
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Figure 3.14a: Serum cytokine concentration of mice treated with anti-HBV HDAds. Serum 
concentrations of cytokines are shown for 0, 6 and 24 hours post injection. The graphs were plotted 
by using the mean and the standard error of the mean (SEM). The statistical significance was 
calculated by using a non-paired student T test. P values less than 0.05 (*), 0.01 or (**) were 
considered statistically significant. 
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Figure 3.14b: Representative dot plots from CBA assay for IL-10, IL-6, TNF-γ, MCP-1, IFN 
and IL-12 for 0 hour and 6 hours.  
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Figure 3.15: Measurement of alanine aminotransferase (ALT) activity. ALT levels in mice 
serum after 0 hour, 72 hours, 1 week and 2 weeks in mice injected with anti-HBV HDAds were 
determined. The dotted line represents the baseline or cut-off point for acceptable values that are 
regarded safe. 
 
 
 
 
 
 
Figure 3.16: Representation of the mice weights following injection. The mice were grouped 
and injected with either saline (A), HDAd28E4 (B) or HDAd-pri-miRNA31/589 (C). The mice 
were weighed 1, 2 and 3 weeks post injection. 
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CHAPTER 4 
4. DISCUSSION 
Despite the availability of an effective vaccine, chronic infection resulting from HBV is currently 
incurable. Current treatments are limited by the development of adverse side effects and antiviral 
drug resistance. The ability to manipulate the RNA interference (RNAi) pathway to regulate gene 
expression has opened a new outlook into gene therapy. RNAi-based gene silencing has shown 
therapeutic potential and it is currently being investigated as a potential novel alternative to current 
HBV treatment. Anti-HBV primary-microRNA (pri-miRNA) sequences, which activate the RNAi 
pathway have been designed and have successfully been used to inhibit HBV replication in vitro 
and in vivo (Ely et al., 2008, Mowa et al., 2014). The major hurdle remains finding safe and 
efficient delivery vectors for these sequences. With their added advantage of natural liver tropism, 
Helper-dependent adenoviral vectors (HDAds) have been used with great success for liver-targeted 
gene therapy. Hence, this study investigated the use of these vectors for delivery of anti-HBV 
RNAi activators. 
4.1 Elimination of the lac Z from HDAds 
For easy assessment of tissue transduction, reporter genes such as lac Z have been co-delivered 
with therapeutic genes in Adenoviral vectors. However, several studies have suggested that the 
immune response to β-galactosidase encoded by the gene therapy vectors result in quicker vector 
clearance and short-term therapeutic effects (Crowther et al., 2014, Sullivan et al., 1997, Morral et 
al., 1997). A study by Chen and colleagues was one of the earlier studies that investigated the 
effect of β-galactosidase specific immune response in vector clearance and shortened therapeutic 
effect (Chen et al., 1997). Interestingly, following the injection of adenoviral vectors expressing 
β-galactosidase, a complete loss of β-galactosidase expression was observed 42 days after injection 
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along with vector clearance at 84 days after injection. Hence the elimination of lac Z in HDAds is 
critical to make HDAds more suitable for treatment chronic HBV infection. As a result of larger 
plasmid size (24-32 kb), cloning into HDAds genome bearing plasmids is tricky. This is mainly 
attributed to lower ligation and transformation efficiency. To overcome this, instead of 
conventional restriction manipulations and T4 ligase dependent cloning, a more efficient 
homologous recombination in E. coli is used (Luo et al., 2007). Electroporation is also used as the 
most efficient way of transforming these plasmids.  However, despite these difficulties, T4 ligase 
mediated ligation and electroporation were successfully used to clone anti-HBV pri-miRNA 
expression cassettes in to the lac Z deficient pD28E4 which is 31.027 kb in size (Figure 3.2).  
 
4.2 AdNG163cys fails to serve as an effective helper virus for 
HDAds production 
HDAds are devoid of all their viral coding sequences thus making them less immune stimulatory 
(Palmer, 2005). However, capsid proteins have been shown to activate innate immunity in non-
human primates as well as in mice. Chemical modification of vector particles has been successfully 
used as a means of improving HDAds transduction as well as reducing capsid specific immune 
response induction (Prill et al., 2011). Chemical modification using amine involves the covalent 
attachment of polyethylene glycol (PEG) to amine functional groups of lysine residues on the 
adenoviral surface. Amine reactive PEGylation has been commonly used to shield epitopes on the 
Ad capsid, however, this approach of PEGylation has been shown to reduce adenoviral 
transduction efficiency [Reviewed in (Kim et al., 2012)]. As a result of this limitation, thiol 
PEGylation was developed; this type of PEGylation involves covalently attaching PEG to cysteine 
residues on adenoviral surfaces [Reviewed in (Kreppel and Kochanek, 2008)]. Recent studies have 
showed that thiol reactive PEGylation improve transduction efficiency and results in homogenous 
particle size (Prill et al., 2011) . Hence, this study investigated the feasibility of using AdNG163cys 
helper virus with cysteine modification in the HVR-5 for production of HDAds that are amenable 
to residue specific and thiol reactive PEGylation. To enable production of HDAds using this 
cysteine modified HV, a previously produced AdNG163cys was first amplified. To determine the 
amount of infectious units (ifus), the HV was subjected to immunocytochemical staining, which 
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stains cells infected with the HV. Interestingly, following staining all infected cells were clumped 
together, making it difficult to count brown stained cells (Figure 3.3). Hence, q-PCR was used to 
determine total viral particles and the values were used to calculate the viral particles required for 
HDAd production. The HV MOI commonly used for HDAd production is 5 vp/cell, however when 
AdNG163cys was used, HDAds could only be produced at an MOI of 20. Interestingly, infection 
of HEK293 cells with cysteine modified and lac Z bearing HDAd (pΔ28E4CMVlacZ) displayed 
similar characteristics of clumped blue cells following X-gal staining (Figure 3.4). This 
aggregation of Ads either before or during infection may results from the crosslinking of the vector 
particles via the sulfhydryl bridges of thiol groups on the cysteine residues. Amplification of this 
virus was unsuccessful, despite the higher HV MOIs used, suggesting that this modification might 
diminish transduction efficiency of the HV or the HDAds produced from it. This was confirmed 
by the fact that infection of cells with AdNG163cys resulted in little or no cytopathic effect as 
compared to AdNG163 with wild type HVR 5 (Figure 3.5).  
To investigate wither the modification results in structural changes of the capsid, transmission 
electron microscopy (TEM) was performed to determine the structural integrity of the cysteine 
modified HV. As compared to the icosadedral capsid observed with the HDAd previously 
produced from unmodified HV (Figure 3.6 B), the structure of AdNG163cys looked deformed or 
collapsed (Figure 3.6 A).  According to Prill and colleagues, these results were unexpected. In 
their study HV with cysteine modification in the HVR 5 was successfully used to produce and 
PEGylate Ads using thiol reactive PEG. This improved transduction efficiency of the Ads (Prill et 
al., 2011). In contradiction and similar to our observations, a study by (Kreppel et al., 2005) 
generated Ad5-based first generation vectors that had been modified by introduction of cysteine 
residues within the H1 loop of the Ad fiber protein. These vectors also formed aggregates due to 
the presence of the cysteine residues. This was however resolved by adding 10 mM of reducing 
agents such tris (2-carboxyethyl) phosphine) (TCEP) and dithiothreitol (DTT). The addition of 
these reducing agents did not interfere with the biological functions of the vectors nor their 
physical integrities. This contradiction raises a necessity to further characterise specific mutations 
that can be introduced in to the Ads capsid without compromising the integrity of the vector 
particle and affecting transduction efficiency. 
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4.3 Successful rescue and amplification of the recombinant HDAds 
with AdNG163 helper-virus 
As a result of the limitations of AdNG163cys HV, unmodified AdNG163 HV was used for the 
production of lac Z deficient HDAds. HDAd plasmids were used to transfect 116 cells, which were 
later infected with AdNG163 at MOI 2. As a control, HDAds containing the lac Z gene 
(pΔ28E4CMVlacZ) were also produced (P0) at MOI 5 and amplified (P1-P5) at MOI 2 using the 
AdNG163 HV. The amplification of HDAdlacZCMV was monitored by X-gal staining.  As 
expected, about 1.11 ×105 ifus/mL were obtained after production. The infectious units per mL 
obtained with every passage showed an increase until ~ 109 ifus/mL were obtained (Table 3.2). 
Maximum titres of 1.19 × 109 ifus/mL were obtained at passage 5 in a 60 mm plate and passaging 
in to 150 mm plates increased the titres to 3.3 × 109 ifu/mL which was enough for large scale 
production. This was  not dramatically different with published findings, which showed that the 
titers of the HDAds should increase until ~ 109 ifu/mL are obtained in a 60 mm plate (Palmer and 
Ng, 2008b).  
 
4.4 Expression of anti-HBV pri-miRNA sequences from liver-
specific MTTR promoter 
RNA polymerase III (Pol III) such as U6 and H1 have been widely used for the expression of anti-
HBV pre-miRNA mimics (shRNAs). However their use has been associated with toxicity as a 
result of the saturation of the RNAi pathway (Grimm, 2006). Pol II promoters have been shown to 
be tightly regulated and safer for expression of RNAi activators. Hence, to avoid toxicity, a study 
by (Ely et al., 2008) compared the expression of shRNAs from Pol II CMV and Pol III U6 
promoters. In vitro and in vivo knockdown of 95-98 % was observed when using U6 promoter to 
express shRNAs, however expression of shRNAs from CMV promoter reduced HBV knockdown 
to from 95 % to ~ 60%. These indicate that shRNAs are not compatible with Pol II promoters. 
Using mimics of pri-miRNAs has more advantages over pre-miRNA mimics as they compatible 
with safer Pol II promoters and enables a better, regulated tissue specific expression. Use of a liver-
specific murine transthyretin (MTTR) promoter to express anti-HBV pri-miRs showed superior 
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pri-miRNA expression in mice livers than non-tissue specific CMV promoter driven pri-miRNAs 
(Ely, 2009, Mowa et al., 2014).  Hence this study used lac Z deficient HDAds to express pri-
miRNA sequences from the liver-specific MTTR promoter. 
In agreement with published data (Mowa et al., 2012, Mowa et al., 2014, Ely et al., 2008), RNA 
isolated from Huh7 cells infected with HDAd-pri-miRNA-31/5 showed the presence of a single 
band of ~21 nt when the blot was probed with guide 5 probe only but not guide 8 and 9 probes 
(Figure 3.9). On the other hand, RNA isolated from Huh7 cells infected with HDAd-pri-miRNA 
31/589 is expected to produce three different guides (Ely, 2009, Mowa et al., 2012, Mowa et al., 
2014) , surprisingly only guide 5 could be detected in this study. This could be because of 
differential efficiencies at which the three guides are cleaved from the pre-miRNA, with guide 5 
being produced more abundantly than 8 and 9 (Ely et al., 2008).  
 
4.5 Silencing of HBV replication and safety of HDAds expressing 
anti-HBV pri-miRNA expression cassettes from the MTTR 
promoter 
The anti-HBV pri-miRNA sequences used in this study have been expressed with the CMV or the  
MTTR promoter before and have been found to significantly inhibit HBV replication in vitro and 
in vivo (Ely et al., 2008, Mowa et al., 2012, Mowa et al., 2014). To confirm in vitro HBV 
replication inhibition mediated by these monomeric and trimeric pri-miRNA expression cassettes 
when lac Z deficient HDAds were used, liver-derived Huh7 cells were transfected with HBV 
genome bearing plasmid and infected with anti-HBV HDAds at MOI of 500, 1000, 2000 and 4000. 
ELISA was used to determine the levels of secreted HBsAg levels. Relative to the empty vector 
(HDAdΔ28E4), cells infected with HDAd-pri-miRNA-31/5 at MOIs 500, 1000 and 2000 
significantly inhibited HBV replication. This was observed for 48 and 72 hours post infection. 
Cells infected with HDAd-pri-miRNA-31/589 resulted in a more prominent and significant HBV 
replication inhibition at MOIs 1000 and 2000. These results are comparable to results obtained by 
(Mowa et al., 2014), where HBV inhibition was also dose dependent after infecting cells with 
HDAds expressing pri-miRNA sequences from MTTR promoter. The common MOIs used in both 
studies are MOI 500 and MOI 1000, in the previous study cells infected with HDAd-pri-miRNA-
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31/5 at MOI 500 showed ~85% knockdown and MOI 1000 showed ~77% knockdown. Whereas, 
in this study cells infected with HDAd-pri-miRNA-31/5 at MOI 500 showed ~10% knockdown 
and MOI 1000 showed ~25% knockdown. For cells infected with HDAd-pri-miRNA-31/589 in 
the previous study at MOI 500 showed ~90% knockdown and MOI 1000 showed ~85% 
knockdown. On the other hand, in this study cells infected with HDAd-pri-miRNA-31/589 at MOI 
500 did not inhibit HBV replication, whereas cells infected with MOI 1000 showed ~90% 
knockdown. These differences may be due to the fact that unlike (Mowa et al., 2014), this study 
used total viral particles (vps) instead of infectious units (ifus) to calculate number of viral particles 
required for the different MOIs. This may result in lower ifus used for the experiments. Previous 
studies have successfully used Ad total viral particles to calculate viral particles required to effect 
a therapeutic effect (Palmer and Ng, 2004), which suggest that viral preparations from this study 
may have lower ifus than those used in previous studies.  
 
While the inclusion of reporter genes is not desirable in vivo, it serves a valuable tool for titration 
of vectors. To improve anti-HBV inhibition, ifus could be determined using DNA from HDAd 
infected cells for q-PCR. This will involve infection of cells with HDAd for 5hrs, total DNA 
isolation and q-PCR with HDAd specific primers.   
 
To assess the ability of these HDAds to silence HBV replication in vivo, HBV transgenic mice 
were injected with empty HDAdΔ28E4 or HDAd-pri-miRNA-31/589. Serum was collected at 0 
days, 1 week and 2 weeks post injection and used for HBsAg ELISA. Surprisingly, HDAd589 did 
not result in any detectable pri-miRNA expression or significant HBV silencing. In comparison to 
published data, expression of these anti-HBV pri-miRNAs from the MTTR should result in 
significant knockdown of HBV replication in vivo (Mowa et al., 2014). There are several reasons 
that may result in these varying results: 1) The nature of the mouse model used in this study can 
also contribute. In our hands, mice with medium HBsAg (OD 0.4-0.6) are the relevant ones and 
demonstrate HBV gene silencing by RNAi activators. However as the majority of the transgenic 
pups born have very high HBsAg levels (OD 0.8-1), these high titter mice were used. Hence, these 
experiments need to be repeated with medium HBsAg level mice. 2) As stated before, the fact that 
total viral particles and not ifus were used may result in poor liver transduction. 3) The HDAds 
used might be inducing a strong immune response that may result in vector clearance and toxicity.  
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To validate whether HD Ad delivery to hepatocytes was adequate, DNA was extracted from livers 
of mice injected with anti-HBV HDAds. Q-PCR was performed and interestingly ~4 × 105 copies 
per µg of hepatocyte DNA for HDAd-pri-miRNA-31/589 were delivered to the hepatocytes. In 
comparison to 2 × 105 copies per µg of hepatocyte DNA of hepatic HDAd observed by (Mowa et 
al., 2014), these copy numbers should be enough to trigger HBV knockdown in vivo. 
To access if  HDAds used induce a strong and sustained inflammatory response, CBA was 
performed to measure the levels of circulating inflammatory markers IL-6, IL-10, IL-12p70, MCP-
1, IFN-γ and TNF before, six hours and 24 hours after injection with saline or HDAdΔ28E4 or 
HDAd-pri-miRNA-31/589 or Poly IC as a positive control. As compared to saline, there was no 
significant induction of inflammatory marker expression at 0, 6 and 24 hours post infection with 
either of the HDAds produced in this study. As expected, poly IC which was used as a positive 
control significantly induced expression of TNF, MCP-1, IL-10 and IL-6 6 hours post infection. 
These cytokines are said to be involved in important steps of humoral and cell-mediated immunity.  
Expression of anti-HBV shRNAs in mice results in hepatotoxicity and fatality in mice (Grimm, 
2006). To assess whether HDAds used in this study are toxic, ALT activity was measured for 0 
hours, 72 hours, 1 week and 2 weeks post injection with HDAds. In agreement with previous 
studies (Mowa et al., 2014), levels of ALT in all the groups remained below the acceptable cut off 
level of 100 U/L at all the time points; therefore, the anti-HBV HDAds used in this study did not 
induce any obvious liver damage. This was confirmed by normal weight gain observed in all the 
mice used in this study (Figure 3.16).  
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5. CONCLUSIONS 
The aim of this study was to design less immunostimulatory HDAds to prolong anti-HBV effects. 
Lac Z deficient recombinant HDAds expressing pri-miRNA mimics from the MTTR promoter 
were successfully constructed. The pri-miRNA mimics (pri-miRNA-31/5 and pri-miRNA-31/589) 
used were able to activate the RNAi pathway, resulting in successful expression and processing 
into mature miRNA strands in vitro. Both pri-miRNA-31/5 and pri-miRNA-31/589 were able to 
significantly knockdown HBV replication in liver-derived Huh 7 cells in a dose-dependent 
manner.  The quantification of circulating inflammatory and liver toxicity markers reaffirms the 
safety of HDAds in the development of novel anti-HBV gene therapeutics. However, long term 
studies are required to determine whether this translates to a sustained HBV replication inhibition 
in vivo. This is the first study to use lac Z deficient HDAds to deliver MTTR promoter driven pri-
miRNAs against HBV. The findings from this study may contribute to the development of RNAi-
based therapeutics with minimised induction of immune response and toxic effects.  
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6. FUTURE STUDIES 
In this study, a helper-virus (HV) with a cysteine modification was used. This HV has been shown 
by others to function in HDAd production without causing and structural changes to the virions. 
However, this was not observed in our study. To understand these contradictions, the HV will be 
taken for sequencing of the Hexon encoding gene to check for additional mutations that may have 
occurred.  
To improve activity of HDAd vectors produced in this study ifus will be determined. 
To better asses in vivo activity of HDAds generated in this study, mice with HBsAg levels of 
around 0.4-0.6 will be used.  
To assess wither the deletion of lac Z from anti-HBV HDAds result in prolonged transgene 
expression and inhibition of HBV replication long term studies will be carried out in mice.  
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7. APPENDIX 
 
All general chemicals were obtained from, Merck, Sigma, Quantum Biotech, Qiagen, 
Thermo Fisher Scientific, Epicentre Biotechnologies 
7.1 Bacterial Methods 
7.1.1 Luria Bertani (LB) media 
Ten grams of tryptone (Quantum Biotech, South Africa), 5 g of yeast extract (Quantum Biotech, 
South Africa) and 5 g NaCl were dissolved in 1 litre of distilled water (dH2O) in a 1 litre lab glass 
bottle and sterilized by autoclaving for 30 min at 121°C and 1 kg/cm2. 
7.1.2 Luria Bertani agar (LA) media 
Ten grams of agar (Quantum Biotech, South Africa ), 10 g tryptone (Quantum Biotech, South 
Africa), 5 g of yeast extract (Quantum Biotech, South Africa) and 5 g NaCl were dissolved in 1 
litre of distilled water (dH2O) in a 1 litre lab glass bottle and sterilized by autoclaving for 30 min 
at 121°C and 1 kg/cm2. 
7.1.3 Ampicillin solution (100 mg/mL) 
One gram of ampicillin was added to 5 mL of dH2O and 5 mL of 100% ethanol. The solution was 
filter sterilized and stored at -20°C. 
7.1.4 Kanamycin solution (50 mg/mL) 
An amount of 0.5 g of kanamycin was added to 10 mL dH2O. The solution was filter sterilized and 
aliquots were made. 
7.1.5 LB Agar plates 
Ten grams of tryptone (Quantum Biotech, South Africa), 5 g of yeast extract (Quantum Biotech, 
South Africa),5 g NaCl  and 10 g bacterial agar (Quantum Biotech, South Africa) were dissolved 
in 1 litre of distilled water (dH2O) in a 1 litre lab glass bottle and sterilized by autoclaving for 30 
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min at 121°C and 1 kg/cm2. Ampicillin (100 mg/mL) or kanamycin (50 mg/mL) was added, and 
the agar solution was poured in bacterial plates and allowed to solidify at room temperature.  
7.1.6 Transformation Buffer 
Transformation buffer was prepared by adding 1.47 g of 100 mM CaCl2, 0.30 g of 10 mM PIPES-
HCl and 15 mL of 15% glycerol in 80 mL of dH2O. The pH was adjusted to 7.0 with NaOH, the 
solution was made up to 100 mL with dH2O and autoclaved for 30 minutes at 121 °C and 1 kg/cm
2. 
Transformation buffer was stored at -20°C. 
7.1.7 X-gal solution (20 mg/mL) 
An amount of 0.2 g of x-gal was added to 10 mL of dimethylformamide, the tube was covered 
with foil and it was stored at -20°C. 
7.2 DNA isolation solutions 
7.2.1 Resuspension buffer (Buffer P1) 
Tris (hydroxymethyl) aminomethane [Tris base (Sigma-Aldrich, South Africa)] (6.06 g) and 
3.72 g Na2EDTA.2H2O (Sigma-Aldrich, South Africa) were added to 800 mL of distilled water 
(dH2O). The pH was adjusted to 8.0 with HCl (Merck Millipore, South Africa) and the volume 
was topped up to 1 L with dH2O. The solution was autoclaved for 20 minutes at 121 °C and 1 
kg/cm2, it was allowed to cool and 100 mg of RNase A was added. The buffer was mixed 
thoroughly and stored at 4 °C. 
 
7.2.2 Lysis buffer (Buffer P2) 
Eight grams of 8 sodium hydroxide [(NaOH), Merck Millipore, South Africa)] pellets and 10 g 
of SDS were added to 500 mL of dH2O, the volume was adjusted to 1 L with dH2O and the buffer 
was stored at room temperature. 
7.2.3 Neutralization buffer (Buffer P3) 
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An amount of 294.5 g of potassium acetate was added to 500 mL dH2O, about 300 mL of acetic 
acid was added to adjust the pH to 5.5. The volume was topped up to a final volume of 1 L with 
dH2O and it was stored at 4 °C. 
7.2.4 QBT buffer 
Sodium chloride (NaCl, 43.83 g) and 10.46 g MOPS were dissolved in 800 mL dH2O. The pH 
was adjusted to 7 with NaOH, 150 mL Isopropanol and 15mL of 10 % Triton X-100 solution (v/v) 
were added. The final volume was adjusted to 1L with dH2O and the buffer was stored at room 
temperature. 
7.2.5 QC buffer 
NaCl (58.44 g) and 10.46g MOPS were added to 800 mL of dH2O. NaOH was used to adjust 
the pH to 7, 150 mL Isopropanol was added and the final volume was adjusted to 1 L with 
dH2O. The buffer was stored at room temperature. 
7.2.6 QF buffer 
NaCl (73.05 g) and 6.06 g Tris base were added to 800 mL dH2O, pH was adjusted to 8.5 with 
HCl and 150 mL of Isopropanol was added. The final volume was adjusted to 1L with dH2O and 
the buffer was stored at room temperature.  
7.2.7 50 × Tris-acetate-EDT (TAE) buffer 
Tris base (242 g) was added to 57.1mL glacial acetic acid, 100mL 0.5 M EDTA (pH 8) was 
added and the volume was made up to 1 L with dH2O. To make 1 L of 1 × TAE buffer, 20 mL 
of 50 × TAE buffer was added to 980 mL of dH2O. 
7.3 Cell culture methods 
7.3.1 Eagle’s Minimum Essential Medium (EMEM) media 
EMEM media was made by taking 28.23 g of EMEM powder and 6.69 g of sodium hydrogen 
carbonate and adding to 3 L of sabax water. This was stirred until completely dissolved and the 
pH was adjusted to 6.8, the media was filter sterilized into autoclaved 1 L bottles and stored in the 
fridge.    
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7.3.2 Dulbecco's Modified Eagle's Medium (DMEM) media 
DMEM media was purchased from Gibco® (Thermo Fischer Scientific, MA, USA) or made 
according to the manufacturer’s instructions.  
7.3.3 Joklik Eagle’s Minimum Essential Medium (JEMEM) media 
JEMEM media was made by taking 33.6 g of JEMEM powder and 6 g of sodium hydrogen 
carbonate and adding to 3 L of sabax water. This was stirred until completely dissolved and the 
pH was adjusted to 6.8, the media was filter sterilized into autoclaved 1 L bottles and stored in the 
fridge.   
7.3.4 Freezing media 
Freezing media was made by adding 5.6 mL media (EMEM/DMEM/JEMEM), 3.4 mL FBS and 
1 mL DMSO in a 50 mL Falcon tube and filter sterilizing it. 
7.4 Northern blot buffers 
7.4.1 TE buffer 
To make 1 L of TE buffer, 1 M Tris-HCl pH8 was added to 2 mL of 0.5 M EDTA pH 8and the 
volume was topped up to 1 L with dH2O. 
7.4.2 Sephadex 
Sephadex G-25 (5 g) was added to 50 mL TE buffer and left rotating overnight at room 
temperature. This was centrifuged for 2 minutes at 5000 g twice and resuspended in 50 mL TE 
buffer. 
7.4.3 10 × TBE buffer 
Boric acid (27.5 g), and 50 g Tris were added to 400 mL dH2O. A volume of 20 mL 0.5 M EDTA 
pH8 was added. The pH was adjusted to 8 and the volume was topped up to 500 mL with dH2O 
and autocaved for 20 minutes. 
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7.4.4 20 × SSC 
NaCl (3 M) and 3 M of Na3C6H5O7.2H2O were added in 800 m dH2O. The pH was adjusted to 7 
and topped up to 1 L with dH2O. 
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